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ABSTRACT 
 
Longitudinal Association between Clinical Biomarkers for Cardiovascular Disease and Disease 
Progression in Chronic Kidney Disease Patients by Race/Ethnicity 
 
Judi Wong, MPH Candidate 
Ellie Kelepouris, MD (Preceptor) 
Longjian Liu, MD, PhD (Advisor) 
 
Background: It is likely that there are ten times more Americans at risk for chronic kidney disease (CKD) 
than there are currently diagnosed. Public health efforts to close this gap with screenings have been 
stalled by the unclear risk factor etiology of CKD.  
 
Objective: A hospital-based study was undertaken to examine the association of clinical biomarkers with 
the risk of incident cardiovascular disease (CVD) and disease progression in patients with early stages of 
CKD by race/ethnicity.  
 
Methods: A total of 289 patient records from the Division of Nephrology were reviewed using a 
retrospective cohort study design. Patients diagnosed from 2007-2009 with CKD, but without CVD at 
baseline, were reviewed using a retrospective cohort study design. Kaplan-Meier models were applied to 
compare time-to-event curves (incident CVD and progression of CKD) by race/ethnicity. Cox 
proportional hazard regression models were used to assess risk factor significance for the events. A CKD 
event was defined as an increase in disease severity by CKD stage progression, and a CVD event included 
angina, atrial fibrillation, congestive heart failure, coronary artery disease, myocardial infarction, or 
stroke. Subjects were evaluated for both outcomes separately. 
 
Results: After excluding records with missing race/ethnicity information, 272 patients remained in the 
study. Of them, 72% were African American 21% were White, and 7% were Hispanic. Overall, 15.1% of 
the patient population experienced a CKD event, while 10.3% experienced a CVD event. The cohort 
incidence of CVD was 28 per 100,000 person-years, but was significantly higher in Hispanic patients 
(183 per 100,000 person-years, p < 0.0001) as compared to African American (48.6 per 100,000 person-
years) and White (49.4 per 100,000 person-years) patients. Relative risks for early CKD progression 
indicate that minorities have less than half the risk of White patients for increase in disease severity, 
though a greater proportion of African Americans will have experienced a CKD or CVD event. 
 
Conclusions: Minorities with CKD seem to fare worse than White patients when evaluated for CVD 
event risks, while White patients seem to have greater CKD severity when compared to minorities. A 
greater proportion of Hispanic patients were observed to enter the study at an earlier stage of CKD as 
compared to African American and White patients. To improve CKD outcomes in all populations, a 
double-model of baseline and changes in risk factors would be useful for healthcare providers to predict 
and control for disease progression in patients with CKD. 
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INTRODUCTION 
 Prevention for chronic diseases have been predominantly focused on aggressively 
attacking heart disease, cancer, diabetes, and most recently, obesity, while less attention has been 
paid to the emerging epidemic of chronic kidney disease (CKD). Ranked as one of the top ten 
leading causes of death in this country (CDC, 2010), CKD is one such disease that has never 
garnered much national media and press coverage. In 2009, it was estimated from the 1999-2004 
National Health and Nutrition Examination Survey (NHANES) that 16.8% of the United States 
population over 20 years of age have CKD (Clark & Khan, 2009), which can be interpreted as 
one out of every six American adults having the disease (approximately 50 million people from a 
total of 300 million people). However, in the same year, it was estimated from the 2008 National 
Health Interview Survey (NHIS) that only 1.7% of the sample population (over 20 years of age) 
had been diagnosed with CKD (approximately one out of every sixty participants: Pleis, Lucas, 
& Ward, 2009). Granted, there are differences in survey questionnaires and methodologies 
between NHANES and NHIS, yet, there still is undoubtedly an obvious and glaring discrepancy 
between (1) individuals who have CKD and are aware of it, and (2) individuals who have CKD 
but are not aware of the fact. It is thus a significant indication that public health needs to step in 
to address this knowledge gap in order to prevent and reduce the mortality and morbidity 
associated with chronic kidney disease. 
 Perazella (2003) remarked that, “There is underdiagnosis and undertreatment of CKD in 
the United States,” making CKD a “silent epidemic” in this country. Indeed, as seen from the 
NHANES and NHIS reports, this is true. More focus in the health care field has been placed on 
individuals with end-stage renal disease (ESRD), since these are the patients in need of daily 
dialysis treatment or possible kidney transplants (i.e., more intensive care required resulting in  
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higher hospital bills). However, ESRD is at the very end of CKD, and thus the hospital cases, or 
the individuals diagnosed with ESRD, represent the more severe cases of renal failure and are 
only the tip of the iceberg of CKD cases prevalent in the United States. A public health 
intervention would most likely promote the treatment of CKD in the early stages (Perazella, 
2003), as well as advocating the general public to be screened for CKD at their physician’s office 
so that the physician may educate the patient on various strategies to control the disease. 
 Times are changing for the better, as is evident with the new Healthy People 2020 
objectives that reflect new attitudes towards CKD (HHS, 2010b). While Healthy People 2010 
only focused on ESRD treatments (HHS, 2010a), Healthy People 2020’s CKD section will 
contain additional proposals to (1) reduce CKD in the United States, (2) increase the awareness 
among people who have CKD but have not been told that they do, and (3) to focus on increasing 
treatment of CKD with the most commonly used medications for renal failure (angiotensin 
converting enzyme inhibitors, ACEIs, and angiotensin II receptor blockers, ARBs: HHS, 2010b). 
All of this is definitely good news, but one main concern that many nephrologists have is that 
there are no concrete risk factors currently in use to screen for CKD in the general population 
(Stenvinkel et al., 2008), unlike for heart disease and diabetes. Thus, in order to effectively meet 
the goals of Healthy People 2020 for CKD, nephrology clinicians and other health care 
professionals will need the aid of scientists in the research field to provide a good description of 
the early etiology of CKD in order to identify dominant risk factors to be used for screenings. 
 To further complicate matters, scientists have also recognized that many pre-existing 
diseases or conditions play huge roles as major CKD risk factors. In particular, diabetes and 
hypertension are the main disease and condition, respectively, attributed with the development of 
CKD (NKF, 2010). Cardiovascular disease (CVD) is also involved as an early CKD risk factor, 
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but it is more known as the strongest predictor of death among severe CKD patients (Clark & 
Khan, 2009; Kalantar-Zadeh, Kovesdy, Derose, Horwich, & Fonarow, 2007; Levine et al., 2001; 
Nickolas et al., 2008; Shah, Polkinghorne, Pellicano, & Kerr, 2008; Stenvinkel et al., 2008; 
Wattanakit, Coresh, Muntner, Marsh, & Folsom, 2006, Weiner et al., 2004). Vice versa, CKD is 
also documented as an important contributing factor for the development of CVD, and the two 
diseases are seen as reciprocating elements that feed into increasing disease severity (Clark et al., 
2009; Kalantar-Zadeh et al., 2007; Levine et al., 2001, Nickolas et al., 2008; Shah et al., 2008; 
Stenvinkel et al., 2008; Wattanakit et al., 2006; Weiner et al., 2004). However, this effect varies 
among different races/ethnicities, in which varying proportions of co-morbidities exist (Kalantar-
Zadeh, et al., 2007), and a study of CKD along with CVD will require focus on the effect of 
race/ethnicity on disease progression and development as well. 
 This study aims to conduct the first longitudinal risk factor investigation of early CKD 
progression among a hospital-based patient population in Philadelphia, Pennsylvania, that will 
address all of the issues associated with CKD research aforementioned. Using patients diagnosed 
with only CKD at baseline, the development of CVD will also be documented in this study with 
risk factors, some of which some may be connected directly with CKD. Upon the conclusion of 
this study, it is hoped that the results will be used to further patient education on the mitigation of 
CKD by preventing or controlling other co-morbidities (such as CVD, diabetes, and 
hypertension), if possible. Mostly, this study will be best employed as a stepping stone for a 
future prospective cohort study conducted in Philadelphia, ideally multi-centered, in order to 
address health disparities among minority populations that make up a significant amount of the 
CKV patient population that continues to grow in this large American city. 
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BACKGROUND 
A.  Understanding Chronic Kidney Disease (CKD) 
 The main role of the kidneys is to filter the blood, cleaning it of excess solutes and 
metabolic waste that would otherwise accumulate to alarmingly harmful degrees in the body 
(NKUDIC, 2009). In the kidneys, the sites of first contact with the blood, in preparation to be 
filtered, are at the glomeruli (glomerulus for singular reference), as depicted in Figure 1 below. 
Crudely, glomeruli may simply be described as balled-up capillary tubes in the kidneys that are 
created from the intertwining of blood capillaries and small, urine collecting tubules of the 
kidneys. The rate at which blood is filtered through the glomeruli is termed as the glomerular 
filtration rate (GFR: NKF, 2002). 
Figure 1: Diagram of the Kidney (NKUDIC, 2009) 
 
 
Development and progression of CKD in a patient is currently measured as the decline in 
GFR, and values of GFR are in turn grouped into stages of CKD as shown in Table 1 on the next 
page. The units of GFR are mL/min/1.73m2, which is interpreted as the flow volume of fluid 
(mL) through the kidney’s glomeruli per minute per body surface area (1.73m2 is the estimated 
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body surface area of an average adult: Weiner et al., 2004). The onset of CKD may be due to 
various factors, such as diseases that afflict the kidney directly (i.e., cancer), or conditions that 
affect blood vessels in general (i.e., hyptertension: NKUDIC, 2009). Ultimately, anything that 
can cause damage to the glomeruli, even physical injuries, can be viewed as a risk factor or 
contributor for CKD.  
Table 1: Stages of CKD (NKF, 2009) 
Stage Description Glomerular Filtration 
Rate (GFR) 
At increased 
risk 
Risk factors for kidney disease (e.g., diabetes, high blood 
pressure, family history, older age, ethnic group) 
More than 90  
1 Kidney damage (protein in the urine) and normal GFR More than 90 
2 Kidney damage and mild decrease in GFR 60 to 89 
3 Moderate decrease in GFR 30 to 59 
4 Severe decrease in GFR 15 to 29 
5 Kidney failure (dialysis or kidney transplant needed) Less than 15 
 
 The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) group met in May 
of 2009 to propose a new and improved method of calculating GFR from an individual’s serum 
creatinine measurement and certain demographic characteristics (Levey et al., 2009). Creatinine 
is a common metabolic byproduct from the wearing down of muscle cells activity due to activity 
on a daily basis (NKUDIC, 2009). It is normally filtered out into the urine by the kidneys, except 
when kidney function begins to fail; a build-up of creatinine in the serum then results. Thus, 
increasing levels of serum creatinine will most likely directly reflect the decreasing filtering 
ability of the kidneys (at the glomeruli), signaling a development of CKD. Many hospitals and 
kidney organizations have adopted this new formula for calculating GFR, and it will also be used 
in this study to calculate subjects’ GFRs to determine their CKD stage. The CKD-EPI equation is 
as follows: 
GFR = a x (SCT/b)c x (0.993)age 
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 The variable a takes on the following values on the basis of race and sex: 
 Black:   Women = 166 
   Men = 163 
 White/Other: Women = 144 
   Men = 141 
 The variable b takes on the following values on the basis of sex: 
   Women = 0.7 
   Men = 0.9 
 The variable c takes on the following values on the basis of sex and SCT measurement: 
 Women: SCT < 0.7 mg/dL = -0.329 
   SCT > 0.7 mg/dL = -1.209 
 Men:  SCT < 0.9 mg/dL = -0.411 
   SCT > 0.9 mg/dL = - 1.209 
 
B.  Review of Current Research in CKD: Measuring CKD Biomarkers/Risk Factors 
 Most recently, on November 3rd, 2009, Clark and Khan (2009) submitted a mini-review 
detailing the current knowledge on outcomes of CKD and what future research should address. 
The first item they addressed was the need for better clinical guidelines for diagnosing a patient 
with CKD. Though CKD is defined by the National Kidney Foundation (NKF) Kidney Disease 
Outcome Quality Initiative (KDOQI: NKF, 2009) as having a glomerular filtration rate (GFR) 
less than 60 mL/min/1.73m2, it is common knowledge that the aging process tends to decrease 
GFR in general. Misdiagnosing a patient (especially the elderly) would cause undue anxiety, as 
well as initiating unneeded treatment that may be costly to both patient and the health care 
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system. Thus, it is imperative that more research is conducted to identify other clinical 
biomarkers (or risk factors) that are clearly associated with CKD, in order to pinpoint meaningful 
risk factors to be used in diagnoses of CKD. For clarification, the current independent criteria 
used by clinicians are (1) identification of kidney damage continuously for three months, and/or 
(2) identification of a GFR less than 60 mL/min/1.73m2 continuously for three months (NKF, 
2002). 
Clark and Khan (2009) also acknowledged that research in the search for CKD risk 
factors is occurring, yet, in many studies reviewed, the investigators depended only on a single 
measurement of a certain biomarker. This creates a severe study limitation. For example, serum 
creatinine was frequently measured at only one point in time, a “one-time measurement (Clark 
and Khan, 2009),” when in truth, serum creatinine varies at different times of the day (and over a 
period of several days). As a recommendation, Clark and Khan (2009) suggested for 
investigators to take a mean of several serum creatinine measurements, and then use that mean in 
conjunction with GFR values to define the CKD status of an individual. Even better are the 
addition of other biomarkers related to CKD, such as proteinuria, to be combined with GFR 
values in the process of constructing a regression model to predict CKD progression. In fact, 
from an impressive, community-based, large cohort study by Weiner et al. (2004), the 
investigators lamented the fact that they could not include proteinuria as a variable in their 
statistical model (due to data limitations in their sample sources).  
 
C.  Review of Current Research in CKD: Measuring CVD Biomarkers/Risk Factors 
As for which CVD biomarkers are to be investigated consistently among CKD patients, 
there is still no consensus. Usually, traditional CVD risk factors, such as age, gender, high 
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systolic blood pressure, serum total cholesterol and HDL cholesterol, diabetes status, and 
smoking status, are included in analyses (Weiner et al., 2004). In many studies, however, 
suggestions have been raised to use non-traditional risk factors as new tools to ascertain CVD 
risk. For instance, Weiner et al. (2004) discussed the possibility of including newly identified 
risk factors in future studies. These biomarkers are known to have a strong link to CVD events, 
and are also highly measureable in subjects with CKD: C-reactive protein, homocysteine, and 
albuminuria. Clark and Khan (2009) also noted that in another study, cystatin C was a better 
predictor for CVD risk than levels of serum creatinine alone, but this was relevant for the elderly 
patient population in particular. Nickolas et al. (2008) also contributed to the discussion that 
proteinuria should also be considered as a risk factor since it is “both a marker of CKD and a 
known risk factor for CVD,” thus mirroring the opinion of Weiner et al. (2004) as mentioned 
previously, but casting proteinuria in a new light with the association to CVD.  
In yet another article, Shah, Polkinghorne, Pellicano, and Kerr (2008) investigated this 
question directly, asking, “Are traditional risk factors valid for assessing cardiovascular risk in 
end-stage renal failure patients (Shah et al., 2008)?” Performing a retrospective cohort study on a 
hospital population of patients on dialysis (and without baseline CVD), the researchers 
concluded that traditional risk factors, such as increasing age, diabetes status, and smoking status, 
were useful in the stratification of the study population when assessing CVD risk. But, they also 
found that non-traditional risk factors, biomarkers that become dominant when a patient has 
Stage 5 CKD and is on dialysis, were actual independent predictors for CVD risk (those being 
vascular calcification and an elevated calcium-phosphate product). The article ended with the 
observation that with all of the various traditional and non-traditional risk factors used in 
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research today, there needs to be an establishment of some sort of standards list for all of the 
factors in order that they may be evaluated and used meaningfully by investigators. 
 
D.  Review of Current Research in CKD as an Independent Risk Factor for CVD 
Returning to the chicken or the egg dilemma, researchers are continuing to search for the 
answer to the question of whether or not CKD itself is an independent risk factor for CVD (and 
vice versa). As Clark and Khan (2009) noted, older studies had used CKD study populations 
with underlying CVD characteristics at baseline, and thus an association between CKD and CVD 
was reported. Now, it is a standard in this field that studying CKD as a risk factor of CVD must 
be grounded in a study population that does not exhibit CVD risk factors at baseline. This is in 
agreement with the analysis made by Levin et al. (2001), concerning future studies.  
One interesting study that incorporated this concept into the study design was an 
investigation by Wattanakit, Coresh, Muntner, Marsh, and Folsom (2006). The researchers 
compared the probability of a congestive heart disease (CHD) event among four study groups 
from the Atherosclerosis Risk in Communities Study (ARIC): 
(1) No CKD and no prior myocardial infarction (MI); 
(2) No CKD, but prior MI; 
(3) Has CKD, but no prior MI; 
(4) Has CKD and prior MI. 
 
Group 2 was considered as the reference group, and when all the other groups were compared 
against Group 2, it was found that Group 4 had the highest risk of CHD and CVD mortality in a 
follow-up period of 15 years, while Group 1 had the lowest. Between those groups, Group 3 had 
the next highest risk compared to Group 2.  
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However, what was evident to Wattanakit et al. (2006) was the observation that having a 
prior MI was a better predictor than using CKD status to predict future CHD events or death 
from CVD. It was especially true among non-diabetic subjects in Group 3 juxtaposed against 
other non-diabetic subjects in Group 2; the risk of CHD and CVD mortality was at least 50% 
lower for the subjects in Group 3. The investigators had chosen subjects without diabetes 
because “it is already considered a CHD risk equivalent (Wattanakit et al., 2006).” Thus, 
diabetes status is a necessary factor to consider when considering variables to analyze subjects, 
and prior MI events should be included in the exclusion criteria for having no baseline CVD.  
 
E. Review of Current Research in CKD: Considerations for Racial Differences and 
Reverse Epidemiology of Traditional Risk Factors in CKD Patients 
 Researchers have also recognized that the progression of CKD and the onset of CVD 
vary among patients of different races/ethnicities. Nickolas et al. (2008), for example, concluded 
that African American CKD patients were at greater risk for CVD events than White or Hispanic 
subjects, in their study of the Northern Manhattan Study (NOMAS) group. For specific CVD 
events, on the other hand, White patients were seen to have a higher prevalence of heart disease, 
while African American and Hispanic patients had higher prevalence of hypertension and 
diabetes. The results of the study might need further verification with another cohort, due to the 
fact that the proportions of individuals representing each ethnicity were not entirely spread 
evenly across the groups (63% Hispanic, 20% African American, and 15% White), but certainly 
demonstrate that the CKD disease state is not the same for all ethnic groups. 
 Weiner et al. (2004) had earlier made the same conclusion as Nickolas et al. (2008) as 
well. After analyzing data from a combined cohort composed of subjects pooled from four large 
community-based surveys (Atherosclerosis Risk in Communities Study, ARIC; Cardiovascular 
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Health Study, CHS; Framingham Heart Study, FHS; and the Framingham Offspring Study, 
termed Offspring), it was seen that CKD was “a more pronounced risk factor for all-cause 
mortality and CVD in African Americans than Whites (Weiner et al., 2004).” The interaction 
between the patient’s kidney function (GFR) and race/ethnicity was assessed, and African 
American CKD patients had the higher adjusted hazard ratio (HR) for CVD events (HR = 1.76, 
95% confidence interval = 1.35 – 2.31) compared to White CKD patients (HR = 1.13, 95% 
confidence interval = 1.02 – 1.26) over a follow-up period of ten years (Weiner et al., 2004). 
Thus, for current research, it is best for investigators to also consider stratifying their subject 
group by race/ethnicity in order to observe the possibly different outcome distributions among 
ethnic groups (the overall HR for CKD patients to have a CVD event, in the study by Weiner et 
al., 2004, was only 1.19, 95% confidence interval = 1.07 – 1.32). 
 More interestingly, Kalantar-Zadeh, Dovesdy, Derose, Horwich, and Fonarow (2007) tie 
in the racial differences with the “reverse epidemiology” seen with traditional CVD risk factors 
in the CKD patient population. That is, CKD investigators have long noted the benefits provided 
to the CKD patient by traditional CVD risk factors (such as obesity, high cholesterol, and 
hypertension; an unexpected “reverse” relationship from that seen in the general population), but 
have also seen differences among ethnic groups. Thus, one will hear of the survival paradoxes 
when comparing patients on the basis of ethnicity and outcomes, or of the “paradoxes-within-
paradoxes” in which one single ethnic group seems to differ from the pattern exhibited by all 
other ethnic groups. Again, for current research, it is important to construct a study capable of 
detecting differences among ethnic groups since it has been established that CKD trends and 
CVD risk factor trends will differ according to the patient’s race/ethnicity. 
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RESEARCH DESIGN AND METHODS 
A.  Specific Aims 
The specific aims of this retrospective cohort study were: 
(1) to describe the epidemiologic characteristics of patients with chronic kidney disease 
(CKD), by race/ethnicity, who received healthcare at the Nephrology Division in 
Hahnemann University Hospital (outcome = progression to next stage of CKD); 
(2) to characterize the development of and co-morbidity from cardiovascular disease (CVD), 
using traditional and non-traditional CVD risk factors, in CKD patients with no baseline 
CVD at the start of the retrospective study, by race/ethnicity (outcome = CVD event); 
and 
(3) to develop improved guidelines for patient education towards an intervention focusing on 
CVD risk factors reduction in CKD patients, with emphasis on race/ethnicity and co-
morbidities. 
 This study was a retrospective cohort study, seeking to ascertain the longitudinal 
association of clinical biomarkers for the progression of CKD and CVD development in patients 
with CKD. Subjects were selected from electronic medical records housed in Hahnemann 
University Hospital, and specifically located in the nephrology clinic in the Nephrology Division 
(chaired by Ellie Kelepouris, M.D., the preceptor of this study). The year selected for the 
retrospective starting point was 2007, so that a follow-up period of at least three years (36 
months) would be achieved by the ending point in 2009. Prior to the start of the study, an 
expedited application was submitted to and approved by the Drexel University Institutional 
Review Board. Recruitment and enrollment procedures were not necessary for this study that 
was chart-review based, so a signed, informed consent form was not required. 
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 Subjects were included based on the following one condition: 
(1) diagnosed with CKD by a nephrologist within the study period of 2007 to 2009. 
  
Subjects were excluded based on the following criteria: 
(1) being seen by a nephrologist for the purposes of dialysis treatment and/or kidney 
transplantation, and 
(2) having baseline CVD history ((prior myocardial infarction, angina, stroke, and 
congestive heart failure). 
 
Since the majority of the medical records had recorded race/ethnicity information, subjects were 
also excluded on the basis of:  
(3) having a racial/ethnic affiliation other than African American, Hispanic, and White. 
 
These criteria established the CKD cohort, with no CVD history, desired for this study. 
 
B. Sample Size Considerations 
 Sample size has been estimated through a series of calculations that assume an equal 
number of subjects in each ethnicity group. Of course, this is certainly will be the case when the 
chart review begins, since it cannot be assumed that there are equal numbers of African 
American, Hispanic, and White patients at the nephrology clinic. However, for calculation’s sake, 
this assumption of equivalent numbers of patients in each group will hold, and the result may be 
considered as a conservative estimate of sample size since the groups will definitely differ in 
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number. Another drawback is the two-group basis of the equations; this study will have three 
groups by ethnicity, and thus, the sample size result will be taken again as an underestimation of 
the true sample size needed, and as a hypothetical analysis example of comparing only two 
groups at a time. 
 Equations and nomograms were utilized from a statistics review article by Whitley and 
Ball (2002). Estimates of group means, standard deviations, and proportions (percents) were 
taken from Weiner et al. (2004) to use as previously established data to be used in this current 
study’s sample size calculations. More than one calculation approach was performed. For the 
detailed analysis, please refer to Appendix A. 
 
C.  Data Collection Methods and Procedures 
Data from the medical records were collected and stored in a database, saved on secure 
password protected desktop and laptop computers, using the database program Centers for 
Disease Control and Prevention’s Epi InfoTM (CDC, 2009). Prior logistical steps in setting up the 
database in Epi InfoTM were completed before data collection was begun, such as creating the 
data entry form for all subjects, which is available in Appendix B. All HIPAA confidentiality 
and security regulations were strictly adhered to, as well as Hahnemann University Hospital’s 
institutional regulations. 
For data analysis, the statistical program SAS 9.1® (Cary, NC) was used to perform the 
following procedures: 
(1) Kruskal-Wallis tests to compare baseline, continuous and numerical data; 
(2) Chi-squared and Fisher’s exact tests to compare baseline categorical data; 
(3) Kaplan-Meier survival analysis on time-to-CKD- and time-to-CVD-development; and 
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(4) Cox proportional hazards regression models to assess risk-factors’ predictability of 
CKD disease progression and CVD development (multiple regression models fit with 
stepwise selection). 
 
CVD development was characterized as a CVD event of (1) diagnosed angina, (2) congestive 
heart failure (CHF), (3) a myocardial infarction (MI), (4) stroke, (5) diagnosed atrial fibrillation, 
(6) other, and (7) coronary artery disease (CAD). 
 
D.  Variables collected 
 As this section will provide a general overview of the variables collected in this study, 
please see Appendix C for a more detailed list of the variables and their coding. 
 Only two pieces of patient identifiable information were collected for the purposes of 
keeping track of the patient medical records reviewed: the medical records number (MRN) and 
date of birth (DOB). Other sensitive personal information such as the name and address of the 
patient were not collected. 
Demographic information included age, gender, race/ethnicity, highest education level, 
and employment status. Behavioral factors incorporated physical activity practices, smoking 
status, alcohol consumption, and vitamin/supplement use. These variables were collected in 
hopes of also including social risk factors into the multivariate models for CKD progression and 
CVD events (for instance, it is expected that smoking greatly affects risk of CVD events, or that 
drinking affects CKD progression). 
Physical examination factors by default were the patient’s height, weight, BMI 
(calculated separately in Microsoft Excel), systolic blood pressure, diastolic blood pressure, and 
heart rate. These and the following clinical measurements were all recorded for each year that the 
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patient was in the study (2007 through 2009), and multiple measurements in one year were 
averaged in order to obtain one value for that one year. 
 Medical history factors were conditions such as having left ventricular hypertrophy or 
being on dialysis, as well as having co-morbidities of diabetes and hypertension. Other co-
morbid diseases were also recorded as a list, then separated into their own respective groups 
during data analysis in SAS©. Medication use and the specific medications were collected and 
modified afterwards in the same manner as the co-morbid diseases.  
 Traditional CKD and CVD risk factors were collected, as well as non-traditional 
measurements. For CKD, traditional risk factors included: serum creatinine, glomerular filtration 
rate (calculated separately in Microsoft Excel), blood urea nitrogen (BUN) and creatinine ratio, 
urine creatinine concentration, urine protein concentration, and red blood cell and white blood 
cell counts. Traditional CVD risk factors included: total cholesterol, HDL, LDL, total cholesterol 
and HDL ratio, triglycerides, and mean plasma glucose concentration. Co-morbid conditions of 
proteinuria and microalbuminuria are also considered traditional CVD risk factors. 
 Serum calcium, phosphorous, potassium, and sodium may all be considered as traditional 
risk factors in both CKD and CVD, as these measurements are commonly part of the metabolic 
panel evaluated in routine laboratory tests from blood draws. These serve the purpose of roughly 
estimating the patient’s ionic balance in the body, but it is also known that the levels of these 
ions affect cardiovascular and kidney function. 
 Non-traditional CKD risk factors incorporated two measurements of serum vitamin D: 
the 25-hydroxy (calcidiol) and the 1,25-dihidroxy (calcitrol, or cholecalciferol) forms. It was not 
recognized until recently that vitamin D measurements are also useful measurements of CKD 
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disease progression, and so it was expected that not a lot of old patient medical records would 
have these results in their lab work reports.  
 Non-traditional CVD risk factors included parathyroid hormone (intact) values, 
hemoglobin levels, hematocrit levels, and hemoglobin A1c (HbA1c), which serves also as a 
surrogate marker for diabetes. These risk factors can also be visualized as non-traditional CKD 
risk factors, and in the multivariate analyses, all of these risk factors will be incorporated into the 
models, regardless of the event being evaluated (i.e., CKD event or CVD event). 
 Event information was collected as follows. There was a general event marker that 
indicated that the patient had a CKD or CVD event, but did not distinguish between the two. For 
that differentiation, two other event markers were created, one for CKD event and another for 
CVD event. The CKD event marker was solely the CKD stage that the patient was currently 
diagnosed in during one year, and thus, each year had a CKD event marker. A true CKD event 
marker was created later in SAS© by evaluating whether or not there was an increase in CKD 
stages across the three years (the time-to-event was recorded as the number of months from the 
time of the first appointment with a nephrologist). The CVD event marker was designed in a 
similar manner, with a CVD event marker present for each year. The true CVD event marker was 
again created later in SAS© as was done for the CKD event marker, and the time-to-event was 
also recorded as the number of months).  
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RESULTS 
A.  Baseline characteristics of the cohort 
Of the 289 charts reviewed, a total of 272 charts were used for the study after 17 were 
excluded for missing race/ethnicity information. Within this cohort, 72.1% of the patient 
population was African American (n=196), 21.0% were White (n=57), and 7.0% were Hispanic 
(n=19); the difference in the number of patients by race/ethnicity was highly significant 
(p<0.0001). The average age of the cohort at baseline was 57.3 years, and the difference in age 
by race/ethnicity was also significant (p=0.0255). African American patients on average were 
58.4 years old, while White and Hispanic patients were relatively younger (57.1 and 47.4 years, 
respectively). In the cohort, the majority of the patients were female (61.8%, n=168), and this is 
observed across the race/ethnicity groups.  These results are summarized in Table 2 below. 
 
Table 2: Age and gender of the CKD cohort by race/ethnicity (n=272) 
 All African White Hispanic P-value† 
 Subjects American      
Total number of records 
(%) 272 (100%) 196 (72.1%) 57 (21.0%) 19 (7.0%) < 0.0001 
DEMOGRAPHICS (percentages calculated by total count in race/ethnicity category) 
Age, years + SD* 57.3 + 17.2 58.4 + 16.7 57.1 + 19.0 47.4 + 14.8 0.0255 
Female 168 (61.8%) 123 (62.8%) 32 (56.1%) 13 (68.4%) 0.5484 
Male 104 (38.2%) 73 (37.2%) 25 (43.9%) 6 (31.6%) 0.5484 
*SD = standard deviation 
 
Table 3 on the next page presents more baseline data on the clinical risk factors collected 
for the cohort. Shown are the distributions of behavioral information, medical history items, 
clinical measurements, and event counts, stratified by race/ethnicity. Categorical variables were 
compared by the Chi-squared test or Fisher’s exact test, while continuous variables were 
compared by the Kruskal-Wallis test (due to unequal numbers per ethnic group).  
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Table 3: Baseline characteristics of the CKD cohort by race/ethnicity 
 
 All African White Hispanic P-value† 
 Subjects American      
Total number of records (%) 272 (100%) 196 (72.1%) 57 (21.0%) 19 (7.0%) < 0.0001 
BEHAVIORAL FACTORS      
Alcohol use, mode (N=251) a ND (N=251) ND (N=180) ND (N=54) ND (N=17) 0.1646 
Education, mode (N=36) b BAC (N=36) BAC (N=20) BAC (N=14) HSD (N=2) 0.0600 
Employment, mode (N=244) c RET (N=244) RET (N=175) RET (N=52) DIS (N=17) 0.0352 
Physical activity, mode (N=238) d NE (N=238) NE (N=171) SE (N=52) NE (N=15) 0.1276 
Smoking, mode (N=253) e NS (N=253) NS (N=182) NS (N=54) NS (N=17) 0.3551 
MEDICAL HISTORY (percentages calculated by total count in race/ethnicity category) 
Diabetes 110 (40.4%) 91 (46.4%) 13 (22.8%) 6 (31.6%) 0.0043 
Dialysis present 5 (1.8%) 4 (2.0%) 0 (0.0%) 0 (0.0%) 0.2474 
Hypertension 222 (81.6%) 167 (85.2%) 40 (70.2%) 15 (79.0%) 0.0343 
Left ventricular hypertrophy 1 (0.37%) 1 (0.51%) 0 (0.0%) 0 (0.0%) 1.0000 
Medication use 243 (89.3%) 174 (88.8%) 52 (91.2%) 17 (89.5%) 0.8697 
Metabolic syndrome f 92 (33.8%) 75 (38.3%) 11 (19.3%) 6 (31.6%) 0.0281 
Microalbuminuria (N=271) 34 (12.5%) 22 (11.2%) 10 (17.5%) 2 (10.5%) 0.4136 
Proteinuria 98 (36.0%) 72 (36.7%) 20 (35.1%) 6 (31.6%) 0.8925 
Reverse epidemiology, 
 presence of characteristics g 
14 (5.2%) 
 
10 (5.1%) 
 
3 (5.3%) 
 
1 (5.3%) 
 
1.0000 
 
Vitamin/Supplement use 87 (32.0%) 57 (29.1%) 23 (40.4%) 7 (36.8%) 0.2467 
CLINICAL 
MEASUREMENTS            
Physical measurements      
Height, inches + SD (N=267) 65.7 + 3.6 65.9 + 3.6 65.8 + 4.2 64.1 + 2.1 0.0940 
Weight, lbs + SD 186.1 + 46.1 190.6 +  44.9 176.6 +  49.2 167.9 +  42.1 0.0200 
BMI, kg/m2 + SD (N=267) 30.4 + 7.1 30.9 + 7.0 28.9 + 7.5 28.4 + 6.8 0.0320 
Systolic BP, mmHg + SD 132.2 + 18.1 133.2 + 17.7 129.5 + 18.4 129.7 + 21.3 0.1352 
Diastolic BP, mmHg + SD 79.3 + 11.1 80.0 + 11.5 77.1 + 9.4 79.4 + 10.5 0.1934 
Heart rate, BPM + SD 79.3 + 12.2 78.7 + 12.2 80.5 + 12.4 83.1 + 12.2 0.2801 
Traditional CKD measures      
Serum creatinine, mg/dL + SD 1.62 + 1.16 1.70 + 1.15 1.48 + 0.76 1.10 + 0.61 0.0021 
eGFR + SD 61.3 + 33.7 59.8 + 33.8 59.6 + 31.1 82.3 + 33.7 0.0224 
BUN/creatinine ratio + SD 
(N=269) 
15.4 + 5.1 
 
14.9 + 4.7 
 
16.9 + 6.3 
 
15.7 + 3.9 
 
0.0599 
 
Urine creatinine, median,  
mg/dL (N=171) 
118.0 
 
131.0 
 
94.0 
 
101.0 
 
0.0082 
 
Urine protein, median, g/dL 
(N=73) 
64.0 
 
52.5 
 
119.0 
 
46.0 
 
0.3104 
 
RBC count, millions/uL + SD 
(N=261) 
4.16 + 0.64 
 
4.13 + 0.65 
 
4.24 + 0.57 
 
4.21 + 0.76 
 
0.6065 
 
WBC count, thousands/uL + SD 
(N=261) 
6.78 + 2.17 
 
6.63 + 2.20 
 
7.21 + 2.11 
 
7.08 + 1.89 
 
0.0750 
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Traditional CVD measures      
Total cholesterol, mmol/L + SD 
(N=213) 
185.5 + 43.8 
 
183.6 + 42.0 
 
186.0 + 46.7 
 
201.0 + 51.5 
 
0.4061 
 
HDL, mmol/L + SD (N=211) 54.6 + 17.1 54.9 + 17.4 55.7 + 18.2 48.4 + 9.7 0.2981 
LDL, mmol/L + SD (N=209) 103.2 + 35.6 102.8 + 36.2 99.3 + 33.9 116.5 + 30.4 0.2127 
Total cholesterol/HDL ratio +SD 
(N=211) 
3.66 + 1.25 
 
3.62 + 1.25 
 
3.53 + 1.03 
 
4.35 + 1.61 
 
0.0631 
 
Triglycerides, mg/dL + SD 
(N=210) 
136.0 + 74.5 
 
129.3 + 61.8 
 
153.1 + 85.4 
 
161.6 + 
124.8 
0.3183 
 
Serum glucose, mg/dL + SD 
(N=270) 
113.6 + 45.3 
 
115.9 + 45.4 
 
98.8 + 25.2 
 
133.5 + 73.0 
 
0.0335 
 
CKD and CVD measures      
Serum calcium, mmol/L + SD 
(N=269) 
9.43 + 0.55 
 
9.45 + 0.51 
 
9.36 + 0.64 
 
9.43 + 0.56 
 
0.7772 
 
Serum phosphorous, 
mmol/L +SD (N=140) 
3.70 + 0.85 
 
3.68 + 0.86 
 
3.73 + 0.79 
 
3.84 + 0.98 
 
0.9790 
 
Serum potassium, mmol/L + SD 
(N=271) 
4.33 + 0.49 
 
4.32 + 0.51 
 
4.37 + 0.45 
 
4.32 + 0.51 
 
0.9619 
 
Serum sodium, mmol/L + SD 
(N=270) 
139.3 + 4.2 
 
139.3 + 4.6 
 
139.3 + 2.9 
 
139.2 + 2.4 
 
0.7457 
 
Non-traditional CKD measures      
Serum 25-hydroxy vitamin D, 
median, ng/mL (N=113) 
24.5 
 
21.0 
 
30.8 
 
22.0 
 
0.5633 
 
Serum 1,25-dihydroxy vitamin 
D, median, pg/mL (N=41) 
30.0 
 
32.0 
 
24.5 
 
(no data) 
 
0.2126 
 
Non-traditional CVD measures      
Parathyroid hormone intact , 
median, log(pg/mL) (N=118) 
79.5 
 
85.0 
 
66.0 
 
78.0 
 
0.4803 
 
Hematocrit, % + SD (N=259) 36.8 + 5.2 36.3 + 5.3 38.3 + 4.3 37.1 + 6.5 0.0303 
Hemoglobin, g/dL + SD 
(N=260) 
12.4 + 1.8 
 
12.2 + 1.8 
 
13.0 + 1.6 
 
12.5 + 2.4 
 
0.0033 
 
Hemoglobin A1c, % + SD 
(N=151) 
7.11 + 2.90 
 
7.31 + 3.16 
 
6.02 + 0.72 
 
7.54 + 2.73 
 
0.0040 
 
Footnotes for Table 3: 
† P-value: Continuous factors were compared by the Kruskal-Wallis test, while categorical factors were compared by 
the Chi-squared test or Fisher’s exact test; shaded cells have significant p-values. 
* SD: standard deviation 
a Drinking status: ND=nondrinker, PD=past drinker, CD=current drinker, AP=addiction problem 
b Educational levels: LHS=less than high school, HSD=high school diploma, VOC=Vocational degree (2-yr degree) 
BAC=Bachelor’s degree (4-yr degree) or higher 
c Employment levels: UNE=unemployed, PTE=part-time employee, FTE=full-time employee, RET=retired, 
DIS=disabled 
d Physical activity: NE=no exercise, SE=some exercise, DE=daily exercise 
e Smoking status: NS=nonsmoker, PS=past smoker, CS=current smoker, AP=addiction problem 
f Metabolic syndrome: presence of diabetes or serum glucose level > 100 mg/dL, and two or more of the following: 
blood pressure > 140/90 mmHg, triglycerides > 50 mg/dL (or HDL < 35 mg/dL (men), HDL < 39 mg/dL (women)), 
BMI>30 kg/m2, presence of microalbuminuria. 
 g Reverse epidemiological characteristics: BMI>30 kg/m2, total cholesterol >200 mg/dL, and/or blood pressure > 
140/90 mmHg. 
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  Behavioral factors presented a challenge to obtain from medical records as only a few 
patient medical histories contained information on educational level, employment status, 
smoking status, alcohol consumption level, and physical activity level. Education level data were 
extremely scarce, as only 36 records out of 272 contained such information. Employment level, 
however, was not as difficult to find, and 244 records contained the information in the patient 
social histories. It was significant that most of the African American and White patients were 
retired, but the Hispanic patients were categorized as disabled (p=0.0352). Table 4 below 
summarizes the behavioral information collected on the cohort, along with the total number of 
records that contained such information for each behavioral risk factor. 
 
Table 4: Baseline behavioral risk factors of the CKD cohort 
Behavioral Risk Factors Average Status  
Alcohol consumption (n=251 records)  Non-drinker  
Educational level (n=36 records)  Bachelor’s  
Employment status (n=244 records)  Retired  
Physical activity (n=251 records)  No daily exercise  
Smoking status (n=268 records)  Non-smoker  
  
 Continuing to the Medical History section of Table 3, it is observed that almost 41% 
(n=110) of all the patients have diabetes, while around 82% (n=222) of the patients have 
hypertension. African American patients, in particular, have percentages higher than this general 
trend (46% and 86%, respectively) and actually have higher proportions of members with 
diabetes and hypertension as compared to White and Hispanic patients (p=0.0043 and 0.0343, for 
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diabetes and hypertension, respectively). The percentages of patients diagnosed with proteinuria 
and/or microalbuminuria are seen in low ranges across ethnicities, and also low overall in the 
cohort (36.0% for proteinuria; 12.5% for microalbuminuria). One record was missing 
information and lab measurements for determining if the patient had or did not have 
microalbuminuria. Figure 2 below summarizes this distribution of diabetes, hypertension, and 
proteinuria by race/ethnicity, and it is seen that White patients in general had less prevalence of 
diabetes and hypertension as compared to the other race/ethnicities. 
 
Figure 2: Selected co-morbidities by race/ethnicity 
 
 The presence of having a metabolic syndrome, was also significant in this cohort 
(p=0.0281). As defined by the WHO, metabolic syndrome is having glucose intolerance or 
diabetes, and two or more of the following conditions (Can & Bersot, 2007; Henley, 
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Wagenknecht, D’Agostino, Jr., Zinman, & Haftner, 2003; Lin et al., 2009; Sandhofer, Iglseder, 
Paulweber, Ebenbichler, & Patsch, 2007): 
- blood pressure > 140/90 mmHg 
- triglycerides > 150 mg/dL, or, 
o HDL < 35 mg/dL (men), HDL < 39 mg/dL (women) 
- BMI > 30 kg/m2 
- presence of microalbuminuria 
White patients tended to not have signs of metabolic syndrome at baseline (only 19.3% did, 
n=11), whereas 38.3% (n=75) of African American patients and 31.6% (n=6) of Hispanic 
patients did. 
In the Clinical Measurements section of Table 3, common vitals measurements are 
presented as well as particular etiological variables and risk factors for CKD and CVD. The 
average weight of the patients at baseline was 186 pounds, while African American patients were 
significantly heavier at 191 pounds as compared to White and Hispanic patients (177 and 170 
pounds, respectively, p=0.0200). As a result, the body mass index (BMI) differences between the 
race/ethnicity groups was also significant (p=0.0320), with African Americans having a higher 
BMI of 30.9 than the overall cohort BMI of 30.4. 
For traditional CKD measures, baseline serum creatinine concentration for the cohort was 
1.62 mg/dL, translating into an estimated glomerular filtration rate (GFR) of 61.3, which in turn 
is interpreted as CKD stage 2, but close to stage 3. African American patients, however, had 
higher baseline serum creatinine (1.70 mg/dL) than White and Hispanic patients (1.48 mg/dL 
and 1.10 mg/dL, respectively, p=0.0021), which meant that African American patients had lower 
GFR measurements (p=0.0224), leading to a more severe stage of CKD at baseline.  
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Not many patient medical records had information on urine creatinine lab measurements, 
but of those which did (n=171), there was a significant difference between race/ethnicity groups 
(p=0.0082). Particularly, White patients had lower urine creatinine concentration (94 mg/dL) as 
compared to African American and Hispanic patients (131 mg/dL and 101 mg/dL, respectively). 
Other traditional CKD measurements did not differ substantially among the race/ethnicity groups. 
For traditional CVD measures, lipid profiles for patients were extremely hard to find. 
Most patients’ lab work reports did not contain data on their total cholesterol, HDL, LDL, and 
triglycerides, and only a total of approximately 200 records reviewed had this information. Thus, 
the lipid profile risk factors were not included in the subsequent Cox proportional hazards 
regression model analyses due to all the missing information. However, serum glucose 
concentrations were usually measured in a complete metabolic panel lab assessment from a 
patient’s blood draw, and it was significant that the values differed between African American, 
White, and Hispanic patients (p=0.0335). White patients had an average baseline glucose 
concentration of 98.8 mg/dL, African American patients averaged 115.9 mg/dL, and Hispanic 
patients averaged 133.5 mg/dL. This is probably a reflection of the prevalence of diabetes within 
each group as discussed earlier.  
 Serum calcium, phosphorous, potassium, and sodium average baseline measurements 
were similar when stratified by race/ethnicity, Serum measurements of two forms of vitamin D 
(25-hydroxy and 1,25-dihydroxy) also did not differ, but it was another type of data that was 
hard to come by in the patient medical records. Not many physicians ordered a lab measurement 
of vitamin D for their patient until the year 2009 (n=113 for measurements on the inactive form, 
n=41 for the active form of vitamin D, as it is a non-traditional CKD risk factor. The same goes 
for the non-traditional CVD risk factors, parathyroid hormone (intact), hematocrit, hemoglobin, 
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and HbA1c. Hematocrit and hemoglobin, however, were relatively easier to find in lab reports 
since they are components of the complete blood count (CBC) panels sometimes ordered by the 
physician for analysis of a blood draw. 
In Table 5 on the following page, measurements of event count (CKD and CVD events) 
data are presented. Overall, 15.1% (n=41) of the patient population experienced a CKD event, 
while 10.3% (n=28) experienced a CVD event. The majority of African American patients had a 
CKD event (16.3%, n=32) as compared to among White patients (12.3%, n=7) and Hispanic 
patients (10.5%, n=2). As for the occurrence of CVD events, a greater proportion of African 
American CKD patients had a CVD event (12.8%, n=25) as compared to White patients (3.51%, 
n=2) and Hispanic patients (5.26%, n=1). Thus, African Americans seemed to experience more 
CKD and CVD events than the other race/ethnicity groups. Between the White and Hispanic 
patients, White patients had more CKD events while Hispanic patients had more CVD events.  
It is also seen in the cohort that for patients with a previous CKD event, the time-until-
CVD-event is on average 1.39 months, but for patients who experience a CVD event first, the 
time-until-CKD-event is much shorter at 0.71 months (these results were not significant across 
race/ethnicity groups). One might surmise that it is more likely for a patient who has experienced 
a CVD event that they will soon have an increase in CKD severity. 
Since the cohort began as patients with no baseline history of CVD, the record of CVD 
event occurrence is also a record of CVD incidence in this CKD cohort. In the study population, 
incidence of CVD was 28.4 events per 100,000 person-years, but was significantly higher in 
Hispanic patients (183 per 100,000 person-years, p < 0.0001) as compared to African American 
(48.6 per 100,000 person-years) and White (49.4 per 100,000 person-years) patients. The 
incidence in Hispanic patients is almost four times greater than the others. 
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Table 5: Event measures of the CKD cohort by race/ethnicity (n=272) 
 All African White Hispanic P-value† 
 Subjects American      
Total number of records (%) 272 (100%) 196 (72.1%) 57 (21.0%) 19 (7.0%) < 0.0001 
EVENT MEASURES (percentages calculated by total count in race/ethnicity category) 
No event 206 (75.7%) 145 (74.0%) 45 (78.9%) 16 (84.2%) 0.5408 
One event (CKD or CVD) 57 (21.0%) 44 (22.4%) 10 (17.5%) 3 (15.8%) 0.6890 
Two events (CKD and CVD) 9 (3.3%) 7 (3.6%) 2 (3.5%) 0 (0.0%) 1.0000 
CKD stage progression 41 (15.1%) 32 (16.3%) 7 (12.3%) 2 (10.5%) 0.7347 
CKD stage at start, mean + SD 2.52 + 1.09 2.57 + 1.08 2.60 + 1.08 1.84 + 1.01 0.0213 
CKD stage at end, mean + SD 2.63 + 1.17 2.68 + 1.17 2.72 + 1.10 1.89 + 1.24 0.0143 
CKD time-to-event, months + SD 17.2 + 11.7 17.9 + 11.6 14.3 + 11.4 18.3 + 12.9 0.0992 
CVD event occurrence 28 (10.3%) 25 (12.8%) 2 (3.51%) 1 (5.26%) 0.0968 
CVD event at baseline 7 (2.57%) 6 (3.06%) 1 (1.75%) 0 (0.0%) 1.0000 
CVD time-to-event, months + SD 17.9 + 12.3 18.4 + 12.1 15.5 + 12.4 19.2 + 14.3 0.2501 
CVD event as CHF 11 (39.3%) 10 (40.0%) 1 (50.0%) 0 (0.0%) 1.0000 
CKD event first 36 (13.2%) 26 (13.3%) 8 (14.0%) 2 (10.5%) 0.9529 
CVD event first 21 (7.7%) 18 (9.2%) 2 (3.5%) 1 (5.3%) 0.4217 
Time-to-CVD event, if CKD event 
occurred first, months + SD 
1.39 + 4.12 
 
1.35 + 4.06 
 
1.51 + 4.25 
 
1.47 + 4.46 
 
0.9439 
 
Time-to-CKD event, if CVD 
event occurred first, month + SD 
0.71 + 2.83 
 
0.86 + 3.15 
 
0.25 + 1.42 
 
0.58 + 2.52 
 
0.3346 
 
CVD EVENT MEASURES (incidence calculated by total person-years in race/ethnicity category) 
Total person-years (p-y) 4856 3607 884 365 n/a 
CVD event occurrence 28 (10.3%) 25 (12.8%) 2 (3.51%) 1 (5.26%) 0.0968 
CVD incidence, per 100,000 p-y 28.4 48.6 49.4 183 < 0.0001 
 
Footnotes for Table 5: 
† P-value: Continuous factors were compared by the Kruskal-Wallis test, while categorical factors were  
compared by the Chi-squared test or Fisher’s exact test; shaded cells have significant p-values. 
 
The stage of CKD at baseline for each patient differed across the race/ethnicity groups. 
Figure 3 below shows the distribution of patients by race/ethnicity and CKD stage at baseline. It 
is observed that more Hispanic patients are seen at CKD stage 1 than all the other patients, while 
African American patients are mostly presenting at the hospital at CKD stage 3. The distribution 
for White patients is similar to the African American patients, except that more White patients at 
CKD stage 2 are present at baseline as compared to the latter group. Both White and African 
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American patients are also arriving at the hospital when they are at stage 5, as opposed to none 
of the Hispanic patients. 
Figure 3: Baseline CKD stage by Race/Ethnicity 
 
Table 6 on the following page presents the average change observed in the clinical risk 
factors collected over the three years of the study. Change is presented as both positive and 
negative values (average increase and average decrease, respectively); thus, data are not 
presented as relative change for each risk factor. In general, the data reflect the picture of disease 
progression in the CKD patients, across the race/ethnicity groups, though none of the differences 
between them were significant.  
Weight loss was common in the cohort, with an average loss of 1.5 pounds, though for 
White patients the average weight change was a gain of 0.72 pounds (almost one pound). Blood 
pressure in the cohort would decrease over the three years (-0.24/-0.58 mmHg), although an 
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increase of 0.35 mmHg in average systolic blood pressure was seen in African American patients. 
Serum creatinine increased by 0.15 mg/dL (with a corresponding decrease in estimated GFR of 
1.51 units), indicating deteriorating renal function, and red and white blood cell counts also 
decreased (0.008 millions/uL and 0.06 thousands/uL, respectively), indicating a greater risk for 
anemia.  
In addition, among the patients who did have vitamin D data available, 25-hydroxy 
vitamin D increased by a very small amount of 0.27 ng/mL over the three years, while 1,25-
dihydroxy vitamin D decreased by 1.13 pg/mL. However, among the White and Hispanic 
patients, 25-hydroxy vitamin D tended to decrease (1.34 ng/mL and 4.63 ng/mL, respectively). 
No data was available for Hispanic patients on 1,25-dihydroxy vitamin D levels, while for White 
patients, there was actually no average change in this form of vitamin D as opposed to the 
decrease for African American patients (1.5 pg/mL). However, as noted before, these observed 
differences were not statistically significant. 
 
Table 6: Observed changes in CKD cohort data from 272 records, by race/ethnicity 
 All African White Hispanic P-value† 
 Subjects American      
Total number of records (%) 272 (100%) 196 (72.1%) 57 (21.0%) 19 (6.99%) < 0.0001 
MEDICAL HISTORY 
CHANGE (percentages calculated by total count in race/ethnicity category) 
Dialysis present 5 (1.84%) 3 (1.53%) 1 (1.75%) 1 (5.26%) 0.3593 
Left ventricular hypertrophy 5 (1.84%) 4 (2.04%) 1 (1.75%) 0 (0.0%) 1.000 
Vitamin/Supplement use 54 (19.9%) 43 (21.9%) 9 (15.8%) 2 (10.5%) 0.4258 
CLINICAL 
MEASUREMENTS CHANGE           
Physical measurements change      
Weight, lbs + SD* -1.50 + 10.76 -2.25 + 11.69 0.72 + 7.39 -0.37 + 8.35 0.2161 
BMI kg/m2 + SD -0.23 + 1.97 -0.35 + 2.13 0.12 + 1.35 0.03 + 1.57 0.1844 
Systolic BP, mmHg + SD -0.24 + 12.19 0.35 + 12.66 -1.77 + 11.23 -1.68 + 9.69 0.5937 
Diastolic BP, mmHg + SD -0.58 + 7.75 -0.44 + 8.30 -1.09 + 6.14 -0.63 + 6.26 0.8544 
Heart rate, BPM + SD 0.61 + 9.45 0.49 + 10.01 1.50 + 8.18 -0.78 + 6.78 0.6230 
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Traditional CKD measures 
change      
Serum creatinine, mg/dL + SD 0.15 + 0.76 0.15 + 0.63 0.14 + 0.92 0.25 + 1.29 0.6604 
eGFR  + SD -1.51 + 11.62 -1.56 + 11.96 -1.89 + 9.22 0.11 + 14.7 0.8581 
BUN/creatinine ratio + SD 0.33 + 2.94 0.36 + 3.16 0.24 + 1.79 0.36 + 3.41 0.8336 
Urine creatinine, mg/dL + SD 6.01 + 60.25 7.42 + 64.61 -2.36 + 21.34 16.3 + 89.9 0.6660 
Urine protein, g/dL + SD -10.2 + 86.3 -13.4 + 102.1 -9.00 + 28.86 17.4 + 38.9 0.4354 
RBC, millions/uL + SD -0.01 + 0.41 -0.011 + 0.447 -0.005 + 0.337 0.012 + 0.242 0.9686 
WBC, thousands/uL + SD -0.06 + 1.40 -0.11 + 1.52 0.04 + 0.85 0.15 + 1.42 0.7163 
Traditional CVD measures 
change      
Total cholesterol, mmol/L + SD -1.66 + 25.72 -0.28 + 27.86 -4.89 + 21.39 -5.35 + 13.02 0.2845 
HDL, mmol/L + SD 1.15 + 7.20 1.52 + 6.82 1.09 + 8.78 -2.06 + 5.26 0.0971 
LDL, mmol/L + SD -1.97 + 21.01 -1.60 + 21.53 -2.12 + 22.69 -4.82 + 9.44 0.6789 
Total cholesterol/HDL ratio +SD -0.07 + 0.63 -0.09 + 0.63 -0.12 + 0.58 0.17 + 0.68 0.3666 
Triglycerides, mg/dL + SD -1.41 + 51.49 -2.15 + 45.51 -7.00 + 53.19 19.6 + 85.5 0.3228 
Serum glucose, mg/dL + SD 2.36 + 25.12 2.57 + 27.69 4.33 + 16.77 -5.63 + 15.06 0.1649 
CKD and CVD measures 
change      
Serum calcium, mmol/L + SD -0.02 + 0.38 -0.02 + 0.41 -0.008 + 0.218 -0.15 + 0.43 0.2080 
Serum phosphorous,  
mmol/L + SD 
0.10 + 0.55 
 
0.09 + 0.40 
 
0.03 + 0.72 
 
0.59 + 1.44 
 
0.1417 
 
Serum potassium, mmol/L + SD 0.04 + 0.37 0.047 + 0.395 -0.001 + 0.329 0.099 + 0.225 0.4250 
Serum sodium, mmol/L + SD 0.17 + 2.64 0.23 + 2.93 0.04 + 1.63 0.00 + 1.91 0.7476 
Non-traditional CKD measures 
change      
Serum 25-hydroxy vitamin D, 
ng/mL + SD 
0.27 + 7.44 
 
1.05 + 7.82 
 
-1.34 + 4.67 
 
-4.63 + 10.36 
 
0.2706 
 
Serum 1,25-dihydroxy vitamin 
D, pg/mL + SD 
-1.13 + 4.49 
 
-1.50 + 5.13 
 
0.00 + 0.00 
 
(no data) 
 
0.4231 
 
Non-traditional CVD measures 
change      
Parathyroid hormone intact, 
median, log(pg/mL) 
16.3 + 85.1 
 
19.8 + 96.1 
 
4.13 + 11.03 
 
0.00 + 0.00 
 
0.7231 
 
Hematocrit, % + SD 0.06 + 3.45 0.031 + 3.612 0.04 + 3.07 0.50 + 2.77 0.8548 
Hemoglobin, g/dL + SD -0.05 + 1.13 -0.055 + 1.156 -0.05 + 1.13 0.11 + 0.89 0.6667 
Hemoglobin A1c, % + SD -0.31 + 2.63 -0.44 + 3.00 0.14 + 0.43 0.07 + 0.24 0.0315 
MEASURES OF INTEREST      
- Total medications used from 
overall top ten, mean + SD 3.31 + 2.09 3.56 + 2.08 2.93 + 2.05 1.79 + 1.47 0.0005 
- Total vitamin/supplements taken 
from overall top five, mean + SD 
0.85 + 1.07 
 
0.88 + 1.08 
 
0.81 + 1.04 
 
0.74 + 1.05 
 
0.8120 
 
- Total co-morbidities present 
from overall top ten, mean + SD 
1.34 + 1.35 
 
1.44 + 1.40 
 
1.04 + 1.25 
 
1.21 + 0.92 
 
0.1234 
 
† P-value: Continuous factors were compared by the Kruskal-Wallis test, while categorical factors were  
compared by the Chi-squared test or Fisher’s exact test; shaded cells have significant p-values. 
* SD: standard deviation 
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 Of the patient charts that did contain a lipid profile, total cholesterol levels tended to 
decrease (average 1.66 mmol/L) while HDL levels increased (1.15 mmol/L). In Hispanic patients, 
the decrease in total cholesterol was more dramatic, at 5.35 mmol/L, and their HDL level 
actually decreased by 2.06 mmol/L as opposed to increasing like the cohort. Figure 4 below 
demonstrates this difference between the Hispanic patients and the rest of the cohort. 
 
Figure 4: Average HDL change by race/ethnicity 
 
 
Following, List 1 presents the top ten medications most commonly used by the CKD 
patients in the cohort, while Table 7 breaks down the top three medications in use by 
race/ethnicity groups. For comparison purposes, it is seen that the top three medications of the 
cohort are (1) diuretics, (2) analgesics, (3) and statins. These three together are not at all 
surprising for CKD patients, since diuretics and statins are for controlling hypertension. 
Analgesics, however, may come as surprise, but if it is recalled that the average age of the 
patients is over 50, it can be reasoned that these patients could be prescribed pain medication for 
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joint problems or general back pain (i.e., lumbago). Table 7 shows that within each 
race/ethnicity group, the top three medications are actually different. All of the patients in each 
group use analgesics, but Hispanic patients do not use diuretics as much as the two other patient 
groups do. White patients also use more statins possibly for control over their cholesterol levels, 
while African American patients use calcium channel blockers to further control their 
hypertension issues. Hispanic patients also use angiotensin receptor blockers more often. 
 
List 1: Top ten medications used by CKD cohort patients 
1 – Diuretics 
2 – Analgesics 
3 – Statins 
4 – Calcium channel blockers 
5 – Angiotensin-converting enzyme inhibitors 
6 – Angiotensin receptor blockers 
7 – Betablockers 
8 – Corticosteroids 
9 – Proton pump inhibitors 
10 – Antidiabetic medication 
 
Table 7: Top three medications used by CKD cohort patients by race/ethnicity 
Race/Ethnicity Medication 1 Medication 2 Medication 3 
African American Calcium channel blockers Diuretics Analgesics 
White Diuretics Statins Analgesics 
Hispanic Analgesics Angiotensin receptor 
blockers 
Calcium channel blockers 
 
 List 2 presents the top five vitamin/supplements used by CKD patients, while Table 8 
breaks down the list accordingly by race/ethnicity groups. Vitamin D, calcium, and multivitamin 
capsules top out the cohort list, and the same items are observed among the race/ethnicity groups, 
except with different orders. Vitamin D is a priority for African American patients, while it is 
second for White patients and last for Hispanic patients. More so, calcium supplements are at the 
beginning of the list for Hispanic patients, while White patients tend to take multivitamins more 
than anything else. 
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 List 2: Top five vitamin/supplements taken by CKD cohort patients 
1 – Vitamin D 
2 – Calcium 
3 – Multivitamin capsules 
4 – Iron 
5 – Folic acid 
 
Table 8: Top three vitamin/supplements taken by CKD cohort patients by race/ethnicity 
Race/Ethnicity Vitamin/Supplement 1 Vitamin/Supplement 2 Vitamin/Supplement 3 
African American Vitamin D Calcium Multivitamins 
White Multivitamins Vitamin D Calcium 
Hispanic Calcium Folic acid Vitamin D 
 
 Last but not least, List 3 and Table 9 on the next page display the list of common co-
morbidities reported in the CKD patient charts, by cohort and race/ethnicity, respectively. 
Excluding hypertension and diabetes (which are actually the predominant co-morbid conditions), 
anemia, hyperlipidemia, and obesity come up as the top three in the cohort (List 3). Anemia may 
or may not be surprising, due to the fact that deteriorating renal function not only affects the 
vasculature of the body, but also the production of erythropoietin by the kidneys in regulating the 
amount of red blood cells produced in the marrow. Hyperlipidemia and obesity may be seen as 
direct effects of the reverse epidemiology previously discussed in the background section. That is, 
as a review, since chronic diseases are wasting diseases, there is a competition between the 
wasting condition and another unhealthy condition in determining what the patient will succumb 
to the quickest. Obese patients tend to “live out” the wasting disease, and thus are the only 
survivors, and lend a survival bias for other patients similar to them. It is interesting to note that 
in Table 9, African American patients have the same order of co-morbidities (since they are the 
majority of the patients in the first place), while Hispanic patients actually have depression (a 
psychological diagnosis) as the second most common condition. 
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 List 3: Top ten co-morbidities present in CKD cohort patients,  
after hypertension and diabetes 
1 – Anemia 
2 – Hyperlipidemia 
3 – Obesity 
4 – Hypercholesterolemia 
5 – Osteoarthritis 
6 – GERD (gastrointestinal/esophageal reflux disease) 
7 – Depression 
8 – Gout 
9 – Hypothyroidism 
10 – Edema 
 
Table 9: Top three co-morbidities present in CKD cohort patients, after hypertension and diabetes 
Race/Ethnicity Co-morbidity 1 Co-morbidity 2 Co-morbidity 3 
African American Anemia Hyperlipidemia Obesity 
White Hyperlipidemia Anemia Hypothyroidism 
Hispanic Anemia Depression Cervicalgia 
 
B.  Kaplan-Meier event models 
Kaplan-Meier graphs of time-to-events, stratified by race/ethnicity, are presented on the 
following page in Figures 5 and 6. In Figure 5, it is seen that for both the White and Hispanic 
patient groups, less than 25% of them experienced a CKD event within 36 months (three years). 
It is a different story for African Americans, where a little over 30% of the patients did have an 
increase in CKD severity. In Figure 6, where time-to-CVD-event is documented, less than 25% 
of individuals in all race/ethnicity groups experienced a CVD event, although the onset of 
disease is of greater severity for African Americans. These differences were not significant. 
From calculations conducted in SAS 9.1©, the incidence of CVD events was 28 per 
100,000 person-years, and CVD incidence was higher in Hispanics (183 per 100,000 person-
years) as compared to African Americans (48.6 per 100,000 person-years) and Whites (49.4 per 
100,000 person-years). The difference in these incidence numbers was statistically significant (p 
< 0.0001). 
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Figure 5: Time-to-CKD-event by Race/Ethnicity a 
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a  Footnote: Hispanic group marked by the black plot; African American by the red plot; White by the blue plot 
 
Figure 6: Time-to-CVD-event by Race/Ethnicity a 
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a  Footnote: Hispanic group marked by the black plot; African American by the red plot; White by the blue plot 
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It was also intriguing to view the time-to-event(s) by baseline stage of CKD. That is, the 
aim of this analysis was to compare CKD and CVD outcomes according to the CKD stage that 
the patient was at in the beginning of the study. In Figure 7 below, it is seen that patients at CKD 
Stage 4 were significantly more likely than the other patients to experience more disease severity 
and progress onto the next CKD stage (Stage 5: p = 0.0449), whereas patients at CKD stage 3 do 
not seem to change much in terms of disease severity. Patients at CKD stages 1 and 2 could 
expect similar disease states at the end of three years, which was relatively better than the 
patients starting off at stage 4, but was relatively worse than the patients at stage 3. CKD Stage 5 
patients were not included due to the fact that stage 5 is the last stage of CKD (end-stage renal 
disease: ESRD), and would therefore not have been able to have had an event. 
 
Figure 7: Time-to-CKD-event by CKD stage at baselinea 
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aFootnote: Stage 1 is marked by the red plot; stage 2 is marked by the orange plot; stage 3 is marked by the green 
plot; stage 4 is marked by the blue plot. 
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 When time-to-CVD-event was analyzed in the same manner, by CKD stage at baseline, 
the results were a little different and not statistically significant (p = 0.4630). In Figure 8 below, 
patients at CKD stage 4 in the beginning continue to have a relatively worse outcome than the 
patients starting off at the other stages of CKD. Patients at stage 3, however, do not show the 
“advantage” as seen before with the time-to-CKD-event analyzed in Figure 7. This case shows 
that stage 3 and stage 2 patients have the same outcome in terms of the proportion of individuals 
surviving up to three years without experiencing as many (or experiencing less) CVD events as 
the patients in stage 4. For patients in stage 1, the advantage of little or no CVD events that they 
seem to hold in the first two years somewhat declines dramatically as they find themselves in a 
similar position with stage 2 and 3 patients by the beginning of the third year. 
 
 Figure 8: Time-to-CVD-event by CKD stage at baselinea 
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aFootnote: Stage 1 is marked by the red plot; stage 2 is marked by the orange plot; stage 3 is marked by the green 
plot; stage 4 is marked by the blue plot. 
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C. Cox proportional hazards regression models 
Four multivariate Cox proportional hazards regression models were constructed (in SAS 
9.1©) b
rence 
 page presents the first model (Model 1) built upon the investigation 
of base
r 
nd 
y using CKD event occurrence with time-to-CKD-event as the combined survival (or, 
event risk) outcome for baseline values of risk factors as well as changes in the risk factor 
measurements (a total of two models), and the same was done in turn for CVD event occur
with time-to-CVD-event as the combined event risk outcome for many of the same risk factors 
(the last two models). In determining the risk factors to include in the models, the backward 
selection method was used. 
Table 10 on the next
line risk factors for CKD in predicting for a CKD event (i.e., increase in disease severity 
represented by progression onto the next CKD stage). Serum creatinine and estimated glomerula
filtration rate were purposely not included in the model due to the fact that those two variables 
directly predict (and calculate for) the stage of CKD a patient will be diagnosed with. The 
traditional lipid profile risk factors (HDL, LDL, total cholesterol, ratio of total cholesterol a
HDL, and triglycerides) were not included the model as well due to missing data present in many 
of the patients for these variables (only around 200 patients had such information). In the best 
interest of creating a significant model, they were excluded, but in a smaller model where they 
were included (results not shown), HDL was found to be a very significant risk factor in CKD 
severity. Even with the lipid profile measurements excluded, the number of observations was 
low, at a total of 236 (86.8% of the original 272 observations).  
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Table 10: Model 1: Baseline CKD Risk Factors Investigation (n=236)*  
Adjusted by Age and Co-morbidities (Proteinuria, Albuminuria, and Diabetes)   
Risk Factor of Interest Relative Risk 95% Confidence Interval P-value 
Race, White (reference) 1.000 -- -- 
Race, African American 0.453 0.165-1.246 0.125 
Ethnicity, Hispanic 0.281 0.047-1.673 0.1633 
Male gender 1.593 0.712-3.564 0.2569 
Increasing smoking habit 1.268 0.873-1.840 0.2121 
Increasing alcohol use 0.582 0.375-0.905 0.0162 
Systolic BP, mmHg 1.016 0.996-1.036 0.1251 
RBC, millions/uL 2.382 0.813-6.981 0.1137 
Serum calcium, mmol/L 0.637 0.352-1.151 0.1348 
Serum sodium, mmol/L 0.901 0.810-1.003 0.0558 
Hemoglobin, g/dL 0.567 0.375-0.858 0.0072 
Vitamin/supplement use from 1.219 
 
0.895-1.660 
 
0.2081 
 top five most common in cohort 
CKD stage at baseline 0.688 0.470-1.008 0.0553 
* Does not include traditional lipid profile risk factors such as HDL, LDL, total cholesterol,  
and triglycerides.      
 
It is seen that White patients have higher risk of CKD stage progression (increase in 
disease severity) as compared to minority patients, whose relative risks are half of the White 
patients (but not statistically significant). Hemoglobin concentration is a very significant and 
protective risk factor (p = 0.0072); higher hemoglobin levels confer a protective effect of more 
than 40% to the CKD patient (this is probably a surrogate marker for presence of anemia), which 
is biologically plausible. What is interesting is the protective effect of increasing alcohol 
consumption (p = 0.0162); this is probably a residue of the reverse epidemiology effect, wherein 
individuals with chronic diseases expressing relatively worse health behaviors and markers seem 
to have a survival advantage over others who may seem healthier. Serum sodium and CKD stage 
at baseline are both borderline significant in predicting for CKD severity. From the previous KM 
modeling results, it is understandable that beginning CKD stage would be an important 
determinant; for sodium, it may be representing the presence of hypertension in the patient. 
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Table 11 below presents the second model (Model 2) built upon the change of risk 
factors in predicting for a CKD event. Change incorporates both positive and negative values; 
this is not a relative change model. Thus, the race/ethnicity variables may not have much 
meaning in this model, but are included for analysis and adjustment purposes. Serum creatinine 
and estimated glomerular filtration rate were again purposely not included in the model as was 
done in Model 1. The traditional lipid profile risk factors (HDL, LDL, total cholesterol, ratio of 
total cholesterol and HDL, and triglycerides) were also not included the model, but in a smaller 
model where they were included (results not shown), triglyceride level changes was a risk factor 
found to be very important in determining CKD severity. The total number of observations used 
in this model was also low, at a total of 231 (84.9% of the original 272 observations).  
 
Table 11: Model 2: Changes in CKD Risk Factors Investigation (n=231)*  
Adjusted by Age and Co-morbidities (Proteinuria, Albuminuria, and Diabetes)   
Change in Risk Factor of Interest Relative Risk 95% Confidence Interval P-value 
Race, White (reference) 1.000 -- -- 
Race, African American 0.875 0.329-2.323 0.7884 
Ethnicity, Hispanic 0.323 0.033-3.155 0.3311 
Male gender 1.494 0.658-3.393 0.3372 
Increasing alcohol use 0.623 0.386-1.008 0.0537 
Increasing vitamin use 2.327 1.007-5.378 0.0481 
Diastolic BP change, mmHg 0.971 0.925-1.019 0.2318 
BUN/creatinine ratio change 0.812 0.728-0.907 0.0002 
Serum calcium change, mmol/L 1.790 0.743-4.314 0.1946 
Serum potassuim change, mmol/L 2.429 1.054-5.597 0.0372 
Serum sodium change, mmol/L 0.833 0.684-1.015 0.0703 
Having comorbidities of the  0.814 
 
0.588-1.129 
 
0.2175 
 top ten most common in cohort 
Time-to-CKD-event 0.808 
 
0.590-1.106 
 
0.1823 
 after a CVD event, months 
 CVD event first 5.992 0.625-57.492 0.1207 
* Does not include traditional lipid profile risk factors such as HDL, LDL, total cholesterol,  
and triglycerides.      
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Again, it is seen that White patients have higher risk of CKD stage progression (increase 
in disease severity) as compared to minority patients, whose relative risks still less than of the 
White patients (but not statistically significant). An increase in serum potassium concentration is 
a very significant and deleterious risk factor (p = 0.0372) for CKD patients; high increases in 
potassium levels increase the risk of having a CKD event by about 140%. This is interesting in 
that many patients were also diagnosed with hyperkalemia; perhaps this is a residual of that 
common co-morbidity, but this may also be due to the effects of taking diuretics that a majority 
of the patients with CKD do. Increasing alcohol consumption again appears as a borderline 
protective risk factor (p = 0.0537) as does increasing serum sodium (p = 0.0703). A new risk 
factor that has emerged is the increasing use of vitamins (p = 0.0481) which raises risk by around 
130%. Normally, one would not associate vitamin or supplement use with adverse outcomes, but 
in the case of CKD patients, this increase in vitamin intake may be correlated with decreasing 
amounts of vitamin D in the body. 
Table 12 on the next page presents the third model (Model 3) built upon baseline risk 
factors in predicting for a CVD event. Left ventricular hypertrophy was purposely not included 
in the model due to the high correlation with congestive heart failure as a CVD outcome. The 
traditional lipid profile risk factors (HDL, LDL, total cholesterol, ratio of total cholesterol and 
HDL, and triglycerides) were not included the model again, and in a smaller model where they 
were included (results not shown), all of them were found to be highly significant in predicting 
for a CVD event. With the lipid profile measurements excluded, the number of observations was 
at a total of 239 (87.9% of the original 272 observations).  
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Table 12: Model 3: Baseline CVD Risk Factors Investigation (n=239)*  
Adjusted by Age and Co-morbidities (Proteinuria, Albuminuria, and Diabetes) 
Risk Factor of Interest Relative Risk 95% Confidence Interval P-value 
Race, White (reference) 1.000 -- -- 
Race, African American 4.925 0.545-44.474 0.1556 
Ethnicity, Hispanic 3.596 0.158-82.019 0.4225 
Male gender 0.377 0.102-1.394 0.1439 
Increasing smoking habit 1.086 0.634-1.861 0.7637 
BMI, kg/m² 1.073 1.002-1.149 0.0444 
Systolic BP, mmHg 0.990 0.963-1.019 0.5050 
WBC, thousands/uL 1.199 0.963-1.493 0.1038 
Serum sodium, mmol/L 0.918 0.843-1.000 0.0504 
Serum glucose, mg/dL 1.005 0.997-1.014 0.2263 
Glomerular filtration rate 0.972 0.923-1.024 0.2825 
Other co-morbidities are 0.626 
 
0.429-0.915 
 
0.0154 
 of the top ten in cohort 
Time-to-CVD event 0.954 
 
0.838-1.088 
 
0.4841 
 after a CKD event, months 
* Does not include traditional lipid profile risk factors such as HDL, LDL, 
total cholesterol, and triglycerides.    
 
It is seen this time around that White patients have less risk of a CVD event as compared 
to minority patients, whose relative risks are almost four to five times greater than that of the 
White patients (but not statistically significant). What was highly significant was the presence of 
multiple co-morbidities from the top ten list of the cohort (p = 0.0154). Even more interesting 
was that this was seen as a protective factor (relative risk = 0.626); again, such a result may be 
due to the effect of reverse epidemiology, that since these “unhealthy” patients have survived 
thus far, their deleterious conditions (such as obesity) seem to confer for them a survival 
advantage. Serum sodium again appears as a borderline protective risk factor (p = 0.0504), and 
BMI actually presents itself as a deleterious one (p = 0.0444). Increase in one unit of BMI seems 
to increase a patient’s risk for a CVD event by 7.3%. It might seem counterintuitive that BMI 
would appear to be an antagonist of CVD when previously the reverse epidemiology effect was 
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discussed. Perhaps if the co-morbid conditions were separated out as risk factors, the reverse 
epidemiology effect would be “controlled for.” 
Table 13 below presents the last model (Model 4) built upon the change of risk factors in 
predicting for a CVD event. Again, the change incorporates both positive and negative values; 
this is not a relative change model. Left ventricular hypertrophy was purposely not included in 
the model as was done in Model 3. The traditional lipid profile risk factors (HDL, LDL, total 
cholesterol, ratio of total cholesterol and HDL, and triglycerides) were also not included the 
model. In a smaller model where they were included (results not shown), triglyceride level 
change and the change in ratio of (total cholesterol/HDL) were risk factors that were found to be 
important in determining a CVD event. The total number of observations used in this model was 
also low like the previous models, at a total of 231 (84.9% of the original 272 observations).  
 
Table 13: Model 4: Changes in CVD Risk Factors Investigation (n=231)*  
Adjusted by Age and Co-morbidities (Proteinuria, Albuminuria, and Diabetes)   
Change in Risk Factor of Interest Relative Risk 95% Confidence Interval P-value 
Race, White 1.000 -- -- 
Race, African American 2.875 0.350-23.621 0.3258 
Ethnicity, Hispanic 2.581 0.127-52.378 0.5370 
Male gender 0.627 0.202-1.941 0.4177 
Increasing smoking habit 1.243 0.789-1.958 0.3481 
Increasing alcohol use 0.766 0.427-1.376 0.3724 
BMI change, kg/m² 1.034 0.833-1.283 0.7613 
Systolic BP change, mmHg 1.011 0.976-1.048 0.5298 
Serum potassium change, mmol/L 2.661 0.781-9.070 0.1176 
Serum glucose change, mg/dL 0.974 0.952-0.997 0.0257 
Glomerular filtration rate change 0.964 0.917-1.013 0.1423 
Other co-morbidities are 0.668 
 
0.445-1.002 
 
0.0513 
 of the top ten in cohort 
Time-to-CVD event 0.956 
 
0.715-1.277 
 
0.7593 
 after a CKD event, months 
CKD event first 0.257 0.007-9.456 0.4599 
* Does not include traditional lipid profile risk factors such as HDL, LDL, total cholesterol,  
and triglycerides.      
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Similar to what was observed in Model 3, White patients again have less risk of a CVD 
event as compared to minority patients, whose relative risks are almost three times greater than 
that of the White patients (but not statistically significant). The presence of multiple co-
morbidities from the top ten list of the cohort was borderline significant in this CVD model (p = 
0.0513), while the only variable that was highly significant was serum glucose change (p = 
0.0257). An increase in glucose confers a protective effect for the CKD patient, but with the 
relative risk at 0.974, the effect is almost close to no effect at all. Serum sodium has disappeared 
from the roster, and what seems to have taken its place is serum potassium; however, the large 
effect of serum potassium change (relative risk = 2.661) is insignificant (p = 0.1176), even 
though the magnitude of the relative risk is impressive.  
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DISCUSSION 
A.  Reflections on the baseline characteristics of the study population 
The high percentage of African Americans in the study population (71.2%, n=196) may 
be reflective of the higher burden of CKD in African Americans, rather than of the local 
population composition. A concurrent study of congestive heart failure patients at the same 
hospital, for example, yielded more White patients (67.9%) than African American patients 
(32.1%: personal communication with Ms. Anjana Patel, May 6th, 2010). Compared with Census 
data, the cohort’s predominance of African American patients is not reflective of the general 
Philadelphia population where 75.1% of individuals are White (75.1%), and only 12.3% of 
individuals are African American (Census, 2000). It is also interesting to note that most of the 
cohort patients are female (61.8%, n=168), while many literature references have found that 
more males than females are diagnosed with CKD (Stenvinkel et al., 2008). At any rate, any 
result from an analysis of the total combined data may be unnecessarily biased by the 
overwhelming data presence from African American patients, so care must be taken when 
interpreting the column “All Subjects” in Tables 2 and 3. Thus, when presenting the results 
stratified by race/ethnicity, calculations of percentages were made by referencing the total 
number of patients in that particular race/ethnic group, not in reference to the total number of 
patients in general (i.e., 272 patients). 
As for the scarcity of behavioral risk factors reported in patient charts, it may reflect the 
presence of information bias. For example, with the education level data, perhaps only 
individuals with higher education experience were more comfortable reporting the fact to the 
physician or on the social history questionnaire (n=36). Employment status data, on the other 
hand, was not withheld as much as (n=244), and this may be just due to the fact that most of the 
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CKD patients were greater than 50 years old and would be expected to be retired. Therefore, it 
does not come as a surprise that sensitive information will be withheld and/or unreported by the 
patient when it is perceived that providing the information has no connection with the medical 
concerns at-hand.  
Data collected are also affected by the physicians’ methods of treating the patient, either 
by focusing only on one symptom of CKD (such as controlling blood pressure) or taking a look 
at the bigger picture. For instance, when labs are ordered to assess the patient for proteinuria or 
microalbuminuria, it may reflect whether or not the patient originally presented to the physician 
with claims for these conditions, and if the physician decided to officially diagnose the patient 
with the condition based upon lab results. Measurements of HbA1c present in labs were also 
dependent on whether the patient disclosed to the physician that they had diabetes, or if the 
physician noticed particularly high serum glucose levels. Thus, there is the large possibility that 
the records with missing HbA1c information are patients that truly do not have or have not yet 
been diagnosed. 
At baseline, White patients seemed to have less co-morbid conditions such as diabetes 
and hypertension, which somewhat correlates into the low percentage (19.3%) of White patients 
having signs of metabolic syndrome as compared to the cohort (33.8%). This may contribute to 
the seemingly smaller magnitude of disease progression in White CKD patients as noted in the 
comparison of relative risks with minorities in the multivariate Cox proportional hazards 
regression models. 
Concerning the collection of non-traditional risk factors for CKD and CVD, it was 
unfortunate that many records had missing data on these risk factors. However, this is probably 
the nature of data collection for these non-traditional measurements; the physician was less likely 
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to deviate from items routinely ordered in lab requests. In the future, physicians will undoubtedly 
order more tests that include non-traditional risk factors, as new research is published on the 
importance of these risk factors (such as vitamin D) and the roles they play in chronic diseases. 
Incidence of CVD events was higher in Hispanics probably due to the chance that such a 
small sample size of this group would yield any event in general. As it was seen from the 
Kaplan-Meier graphs, a greater proportion of African American patients were more afflicted 
with CVD events over time, and it would have expected that this group would have a higher 
incidence of CVD. Another possible factor is that Hispanic patients may not have stayed as long 
in the study as African American and White patients, so that the person-years contributed by 
Hispanic patients was low and inflated the incidence. Nevertheless, attention should be paid to 
the CVD risk of Hispanic patients presenting at the hospital with CKD, and a future study should 
attempt to incorporate a higher number of Hispanic patients. 
 
B.  Changes in risk factor levels over the three years 
As was demonstrated in Figure 4, concerning the dissimilarities in the average change of 
HDL over three years, different race/ethnicity groups have difference outcomes. With the 
Hispanic patients, their particular HDL change outcome may be due to underlying factors, such a 
predominance of hyperlipidemia among the CKD patients. This example just goes to show that it 
is important to analyze cohort data stratified by race/ethnicity, especially when studying chronic 
diseases, in order to observe differences in changes in common risk factors (such as the lipid 
profile) between patients.  
Medication use, vitamin/supplement use, and presence of multiple co-morbidities may all 
be used to predict disease severity. Over time, as the patient needs to use more pharmaceuticals, 
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or develops other health problems, it should be a definite sign to the physician that the patient’s 
condition is deteriorating. At which point or number of items that the patient has accumulated 
should the physician begin to worry is unknown, but that is where the role of a model that 
incorporates these elements come into play as a useful predictive tool for disease progression. 
As for vitamin and supplemental use over the study period, several complications 
accompany the interpretation of this type of data due to the fact that many older individuals (i.e., 
over the age of 50) probably already take vitamins or supplements on their own, and thus the 
consumption of these products may seem to represent characteristics common to particular 
patients. In addition, sometimes the patient may not report to the physician any type of vitamin 
or supplement use since the patient might not consider it as a type of medication. On the other 
hand, physicians will also tend to prescribe certain vitamin/supplements as medication for the 
patients, so that it becomes unclear whether they do so out of consideration for the patient’s age 
or truly for disease mitigation. 
 
C. Kaplan-Meier and Cox proportional hazards regression models 
 From the models for CKD, it was noted that serum sodium plays a large role in predicting 
for disease progression by a baseline measurement as well as a change in its concentration over a 
few years. Thus, any model to be constructed (perhaps for screening) in the future should 
incorporate the measurement of sodium as an important risk factor. Serum potassium was also 
seen to have a significant effect on disease progression when the change in serum potassium 
levels is inspected (rather than baseline measurements). This measurement should probably be 
used with serum sodium measurements in determining CKD disease progression risk, since 
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sodium is perceived as a protective factor in the model while potassium displays an antagonistic 
effect.  
 The protective effect of increasing alcohol consumption, again, is rather an artifact of the 
reverse epidemiology phenomenon. On the other hand, the baseline stage of CKD that the patient 
first presents to the physician is very important, since it was discovered that patients beginning at 
CKD stage 3 do not have as worse outcomes (in terms of increasing disease severity) as 
compared to the patients at the other stages, over a period of three years. Future models should 
be able to take that discovery into account so that patients diagnosed at stage 2 will receive more 
attention and care to prevent then from progressing quickly into stage 3. 
 As for CVD incidence predictor modeling for CKD patients, serum sodium again 
emerges as an important risk factor with the baseline data. For the risk factor changes data, 
however, the change in glucose levels seem to play a more significant part as a predictor. Sodium 
is definitely a heavy player in hypertension, while glucose levels are associated with the patient 
being diabetic or not. Thus, to reduce the risk for a CVD event incidence, a model should show 
accordingly that the early control of salt intake in the patient’s diet and the good management of 
diabetes (if the patient does have diabetes) will be key for avoiding CVD events in CKD patients. 
After all, CVD events are also risk factors for CKD disease progression, and it will be 
advantageous to put effort into promoting cardiovascular health in CKD patients as well.  
 
D.  Limitations and contributions of this study 
The greatest limitation encountered in this study was the sample size of the patients. 
From an original 289 count, the number dwindled to 272 after discarding records with missing 
race/ethnicity information, and then further whittled down to 230-240 for multivariate modeling 
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due to other missing information. However, 230 records still represent a fair amount of patients 
seen at one division of a hospital for a period of three years, and this study also goes beyond 
other studies in presenting results by race/ethnicity.  
As discussed earlier, the patient population of Philadelphia, and this particular hospital, 
may be different from other cities; thus, the study design should be tailored to the circumstances 
at-hand instead of mimicking other studies done at a national level or in other countries with 
contrasting racial/ethnic make-up. What would improve on this study is a corresponding 
retrospective cohort study that is carried out at other high-volume hospitals in Philadelphia (there 
are at least two others). In this manner, many CKD patients in Philadelphia should be covered 
and the results of the study may be generalized to all persons diagnosed with CKD in the city.  
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CONCLUSIONS 
 Minorities with CKD seem to fare worse than White patients when evaluated for CVD 
event risks, while White patients seem to have greater CKD severity when compared to 
minorities. This pattern is also seen in patients with congestive heart failure (CHF: personal 
communication with Ms. Anjana Patel), in which African American patients have worse 
outcomes as compared with White patients. The difference in disease outcomes between CKD 
and CVD should be further investigated by modeling the CKD and CHF patients together and 
identifying similar (or disparate) biomarkers that play a role in both diseases. 
It is also intriguing, in a positive manner, that a greater proportion of Hispanic patients 
are seen at the hospital at an earlier stage of CKD, which may or may not be related to a 
difference in access to health care. Further research may be warranted in terms of the type of 
health insurance each patient has in order to utilize healthcare services in the hospital. Perhaps by 
comparing health plans, something may be gleaned from identifying a plan that seems to confer 
better (or worse) outcomes for the patient, stratified by race/ethnicity. 
In general, to improve CKD outcomes in all populations, a double-model of baseline and 
changes in risk factors would be useful for nephrologists to predict for CKD stage progression 
and CVD event risk as a form of a prevention practice for their patients. With these tools, the 
physician should have the power to say, “If a patient came to me with a particular baseline 
measurement, and the next time the measurement changed by a certain amount, I would like to 
be able to predict from those two pieces of data what the patient’s outcome might be,” and public 
health practitioners may also use them to screen for individuals at risk for CKD, which would be 
the ideal result of such research. 
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Appendix A: Sample Size Analyses 
A.  Sample Size Calculation for a Difference in Means (Equal Sized Groups) 
 If total cholesterol is the CVD risk factor of interest, the target difference is the difference 
in mean total cholesterol between two groups, and the standard deviation would be the higher of 
the standard deviations of the two groups. From Weiner et al. (2004), the mean total cholesterol 
was 225 + 45 mg/dL for White patients, 216 + 47 for African American patients. The target 
difference is therefore 9 mg/dL, and the standard deviation taken will be 47 mg/dL. Subsequently, 
the standardized difference (equation 1 below) will be 0.191. To complete the sample size 
calculation, the nomogram (shown below in Figure A1) will be utilized. 
 
 
Figure A1: Nomogram from Whitley and Ball (2002) 
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The left hand axis contains values for the standardized difference, while the right hand axis 
contains values for desired power. To obtain the estimated sample size (n), a line is drawn from 
the left axis to the right axis, connecting the corresponding values for the standardized difference 
calculated and the power level desired. Where the drawn line crosses the lines on the plot 
determines the sample size, based upon the desired significance level (0.05 or 0.01). 
 In the case for the total cholesterol calculation, the standardized difference was 0.191, the 
desired power is 0.80, and the significance level is 0.05. Estimated n for each group is 700 
subjects. For a total of three groups (with equal size), that brings the total estimated sample size 
to be approximately 2100. Less than that number will result in a decrease in power. 
 
B.  Direct Sample Size Calculation for a Difference in Means (Equal Sized Groups) 
 There is also another equation for the direct estimation of sample size (n) given by 
Whitley and Ball (2002) in equation (2) below. 
 
 
 d represents the standardized difference as calculated by Equation 1 previously. The 
cp,power represents a constant obtained from a table (shown below in Figure A2), determined by 
the significance level and power desired. 
Figure A2: Table for Power Calculations from Whitley and Ball (2002) 
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 In the case for the total cholesterol calculation, the constant is 7.9 (p = 0.05, power = 80%) 
and the d is 0.191. The subsequent estimated sample size calculation yields n = 433, which is the 
sample size for each (equal-sized) group. With three groups, the total estimated n will be 1299 
subjects, or simply 1300 subjects. 
 It is highly unlikely that a total of 2100 subjects will be found from the relatively small 
nephrology clinic at Hahnemann University Hospital, whereas 1300 subjects would be more 
likely. Taking that number as a preliminary estimate, further research will be pursued to find a 
more appropriate equation to calculate a total sample size for a three-group comparison. 
 However, the most recent article on methods on calculating sample sizes for more than 
two groups was published in 1989 by Day and Graham (1989). Trying out their novel nomogram 
design, a sample size for three groups was carried out, as well as a test run for two groups.  
 
C.  Two groups, Day and Graham (1989) 
 Utilizing data from Weiner et al. (2004), the mean and standard deviation of creatinine 
measurements for White and Black subjects were obtained to calculate a hypothetical sample 
size per group, for a total of two groups. Day and Graham (1989) outlined the following 
procedure for calculations: 
(1) Calculate the difference parameter, 9λ : 
(standard deviation of previously determined means of the groups) 
(previously determined standard deviation of the means) 
(2) Find sample size via nomogram: 
a. Bottom horizontal axis = the difference parameter 9λ 
b. Left vertical axis = the power 
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c. Top horizontal axis = the sample size of each group 
 
For example, from Weiner et al. (2004), the mean and standard deviation of creatinine 
measurement was 1.3 + 0.3 for White subjects and 1.6 + 0.5 for Black subjects. The “standard 
deviation of previously determined means of the groups” portion for the difference parameter 
would simply be the standard deviation calculated with the means, 1.3 and 1.6 (SD = 0.212). 
Then, the “previously determined standard deviation of the means” would be the standard 
deviation that was published for the original means. If the standard deviations for the means are 
different, the investigator would just have to choose one of them. In this case, 0.5 was chosen, as 
it was the larger of the two and constitutes a more conservative choice. Finally, the difference 
parameter is calculated by (0.212 / 0.5) resulting in a value of 0.424. 
Using the nomogram displayed in Figure A3 on the next page, the following order of 
operations is used to find the sample size: 
(1) Find the difference parameter on the bottom horizontal axis (the bottom half of the 
scale); draw a horizontal line upwards. 
(2) On the horizontal line, draw a vertical line that intersects through the desired power 
on the left vertical axis; label the intersection of the horizontal and vertical line as 
point A. 
(3) Moving to the bottom left corner of the nomogram, select the appropriate point for 
total number of groups (from the cluster of points) at the desired significance level 
(5% or 1%); draw a diagonal line upwards that intersects through point A. 
(4) Finally, find the appropriate horizontal line at the top of the nomogram, that matches 
the total group number and significance level, and which the previously drawn 
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diagonal line intersects; at the intersection, draw a straight horizontal line upwards to 
find the sample size per group at the top horizontal axis (the top half of the scale). 
Figure A3: Nomogram from Day and Graham (1989) 
 
 
The resulting sample size analysis using the previously mentioned Weiner et al. (2004) creatinine 
data for White and Black subjects, using the Day and Graham (1989) method, was a value of 50 
subjects per group. This value seems incredibly small, when compared to the prior 700 value 
calculated using the Whitley and Ball (2002) method. If the glomerular filtration rate (GFR) data 
from Weiner et al. (2004) is used (mean + SD: 51.9 + 7.3 for White subjects, and 49.6 + 10.0 for 
Black subjects), however, the sample size per group increases to 600 per group, which may seem 
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more reasonable. These differences indicate that sample size calculation depends on the 
variability of the variable one uses in the calculation; for relatively similar values across the 
groups, sample size calculated per group will be small, and for differing values across groups, 
sample size calculated per group will be large. 
 
D.  Three groups, Day and Graham (1989) 
 When a calculation for sample size for three groups was attempted, using data from 
Nickolas et al. (2008) for creatinine data of White, Black, and Hispanic subjects (mean + SD: 
1.0 + 0.3, 1.0 + 0.3, 0.9 + 0.3, respectively), the value returned was 100 per group. Again the 
value per groups still seems rather small, since the number of subjects for the groups combined 
together results in a total of 300 subjects only.  
 Nevertheless, as concluded at the end of the Whitley and Ball (2002) calculations above, 
collection of data will be attempted on a total of 1000 subjects, and hopefully will provide 
enough power to perform comparisons between ethnicities if ethnic data is available in the 
medical records. 
 
E. SAS 9.1© Sample Size and Power analyses (post-study-design phase) 
 Upon the completion of the chart review, power and sample size analyses were conducted 
in SAS©. Essentially, the process was a done in a reverse manner; that is, the ideal sample size 
was calculated from an ideal power, and the results were compared to the sample size on hand 
(289 charts total). It was evident that the power depended on the certain variable one wished to 
analyze specifically, and that the group sizes for each ethnic group, for example, ranged from as 
small as 31 (when considering serum creatinine concentration as the main risk factor of interest, 
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results shown in Figure A4) or 87 persons per group (when considering glomerular filtration rate 
as the main risk factor of interest, results shown in Figure A5). The drawback to the SAS© 
procedure, however, is that the program assumes that there will be equal numbers of samples in 
each group, which is obviously not the case in this study.  
Figure A4: Sample Size by Serum Creatinine Considerations (SAS©)                                    
 
The POWER Procedure 
Overall F Test for One‐Way ANOVA 
Fixed Scenario Elements 
Method                         Exact 
Alpha                           0.05 
Group Means           1.56 1.77 1.22 
Standard Deviation              1.17 
Nominal Power                    0.8 
 
Computed N Per Group 
Actual    N Per 
Power    Group 
0.802       87 
 
Figure A5: Sample Size by GFR Considerations (SAS©) 
                                         The POWER Procedure 
                                   Overall F Test for One‐Way ANOVA 
                                       Fixed Scenario Elements 
                               Method                            Exact 
                               Alpha                              0.05 
                               Group Means           58.37 59.06 82.32 
                               Standard Deviation                33.78 
                               Nominal Power                       0.8 
 
                                         Computed N Per Group 
                                           Actual    N Per 
                                            Power    Group 
                                            0.806       31 
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Appendix C: List of Variables Collected in this Study, with Coding 
Information 
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Patient identifiable information 
MRN Medical Record Number 
DOB Date of Birth (MM-DD-YYYY) 
 
Demographics 
AGE Age (across three years) 
07, 08, 09 
 
GEN Gender  
 0=Female 
1=Male 
 
ETH Ethnicity  
0=non-Hispanic White 
1=non-Hispanic Black 
2=Hispanic 
 
EDU Educational Level (across three years) 
07 0=Less than high school 
08 1=High school diploma received 
09 2=Associate’s/2-yr degree 
3=Bachelor’s/4-yr degree or higher 
 
EMP Employment Status (across three years) 
07 0=Unemployed 
08 1=Employed/part time 
09 2=Employed/full time 
 3=Retired 
 4=Disabled 
 
Behavioral factors 
SMK Smoking status (across three years) 
07 0=Never smoked 
08 1=Past smoker 
09 2=Current smoker 
 3=Addiction problem 
 
 
ALC Alcohol consumption status (across three years) 
07 0=Never user 
08 1=Past user 
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09 2=Current user 
 3=Addiction problem 
 
PHY Physical activity status (across three years) 
07 0=Never exercise 
08 1=Some exercise 
09 2=Daily exercise 
 
VIT Vitamin supplement(s) consumption (Yes/No: across three years) 
07 0=No 
08 1=Yes 
09 
 
VITO Vitamin supplement(s) taken if “Yes” for VIT, across three years if needed 
 (create categories as needed at the end of data collection) 
 
Physical examination factors 
HGT Height – if needed, average for each year 
07 (in inches: 1 meter=3.2808399 feet, 1 cm=0.393700787 inches) 
08 
09 
 
WGT Weight – average for each year (in pounds: 1 kg=2.20462262 pounds) 
07, 08, 09 
 
BMI Body Mass Index (BMI: average for each year, create from HGT and WGT data) 
07 [WGT(lbs) x 703] / (HGT(in)^2) 
08 
09 
 
SBP Systolic blood pressure (mmHg: average for each year) 
07, 08, 09 
 
DBP Diastolic blood pressure (mmHg:  average for each year) 
07, 08, 09 
 
BPM Heart rate (bpm: average for each year) 
07, 08, 09 
 
Medical history factors 
LVH Left ventricular hypertrophy (Yes/No: across three years) 
07 0=No 
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08 1=Yes 
09 
 
DLY Dialysis status (Yes/No: across three years) 
07 0=No 
08 1=Yes 
09 
 
DBM Diabetes status (Yes/No: across three years) 
07 0=No 
08 1=Yes 
09 
 
HTN Hypertension status (Yes/No: across three years) 
07 0=No 
08 1=Yes 
09 
 
MED Medication use (Yes/No: across three years) 
07 0=No 
08 1=Yes 
09 
 
MEDO Medication(s) used if “Yes” for MED, across three years if needed 
 (create categories as needed at the end of data collection) 
 
CMB Other health problems (co-morbidities: across three years) 
07 (create categories as needed at the end of data collection) 
08 
09 
 
Laboratory measurements 
Traditional CKD measures: 
GFR2 Glomerular filtration rate (mL/min/1.73 m2) – average for each year 
07, 08, 09   
 
SCT Serum creatinine (mg/dL) – average for each year 
07, 08, 09 
 
BUN BUN/creatinine ratio – average for each year 
07, 08, 09 
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UCT Urine creatinine (mg/dL) – average for each year 
07, 08, 09 
 
UPT 24-hr urine protein (g/L) – average for each year 
07, 08, 09 
 
RBC RBC count (million/uL) – average for each year 
07, 08, 09 
 
WBC WBC count (thousands/uL) – average for each year 
07, 08, 09 
 
Traditional CVD risk factors: 
TCH Total cholesterol (mmol/L) – average for each year 
07, 08, 09 
 
HDL HDL (mmol/L) – average for each year 
07, 08, 09 
 
LDL LDL (mmol/L) – average for each year 
07, 08, 09 
 
TOH TCH/HDL – total cholesterol/HDL – average for each year 
07, 08, 09 
 
TRI Triglycerides (mg/dL) – average for each year 
07, 08, 09 
 
MPG Mean plasma glucose (mg/dL) – average for each year 
07, 08, 09 
 
PTU Proteinuria (Yes/No) – across three years 
07 0=No 
08 1=Yes 
09 
 
 
 
 
ALB Microalbuminuria (Yes/No) – across three years 
07 0=No 
08 1=Yes 
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09 
 
CA Calcium (mmol/L) – average for each year 
07, 08, 09 
 
PO Phosphorous (mmol/L) – average for each year 
07, 08, 09 
 
K Potassium (mmol/L) – average for each year 
07, 08, 09 
 
NA Sodium (mmol/L) – average for each year 
07, 08, 09 
 
Non-traditional CKD risk factors: 
VITD Serum 25-hydroxy calcidiol, vitamin D (ng/mL) - average for each year 
07, 08, 09 
 
N5DH Serum 1,25-dihydroxy cholecalciferol, calcitrol, vitamin D (pg/mL) – average for each  
year 
07, 08, 09 
 
Non-traditional CVD risk factors: 
PTH Parathyroid hormone (PTH: log (pg/mL)) – average for each year 
07, 08, 09 
 
HB Hemoglobin (g/dL) – average for each year 
07, 08, 09 
 
HCT Hematocrit (%) – average for each year 
07, 08, 09 
 
HAC Hemoglobin A1C (HbA1c: %) – average for each year 
07, 08, 09 
 
 
 
 
 
Event Information 
STTS Overall event status 
 0 = No event 
71 
 
72 
 
 1 = Event 
 
 
CKDmo   Time until CKD event (months) 
 
 
CKD CKD stage – for each year 
07 1 = Stage I 
08 2 = Stage II 
09 3 = Stage III 
 4 = Stage IV  
 5 = Stage V (end-stage renal disease, ESRD) 
 
 
CVDmo  Time until CVD event (months) 
 
 
CVD CVD event – for each year 
07 0 = No event 
08 1 = Angina 
09 2 = CHF   
 3 = MI 
 4 = Stroke 
 5 = Atrial fibrillation 
 6 = Other 
 7 = CAD 
 
